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Abstract 
Inflammation and cells of the innate immune system are known to contribute to tumour 
initiation and progression. Differently, the adaptive immune response controls growth and 
dissemination of established tumours . The double edge role of inflammatory and adaptive 
components of immune system in solid tumours are well represented in CRC. The progression 
and survival of patients with CRC is known to be modified by the interactions generated 
between the tumour and the host’s response in a milieu named tumour microenvironment, 
composed by local immune responses. The quantification of the density and the type of 
immune cells in the tumour microenvironment has been a challenge since the early 60’s of the 
last century. However their role and clinical significance in different human cancers has not 
been unequivocally addressed and still there is a strong interest  in determining the dynamics 
of immunosurveillance and immunoevasion, and the role of immune cells infiltrating CRC. 
Recently, experimental support was provided that cancer infiltrating immune cells might be a 
crucial factor in chemotherapy mediated tumour cell death. Despite effort in this field there’s 
still no clinical evidence in CRC regarding any effect modification by tumour infiltrating cells 
in enhancing the benefit of chemotherapy treatment, or whether this parameter might help to 
identify patients who would benefit from adjuvant therapy. In this context, tumour associated 
macrophages (TAM) represent the prevailing population in different cancers and are thought 
to enhance tumour cells proliferation and survival. Tissue macrophages are players of the 
innate immune response capable of phagocytosis and antigen presentation, that play a key role 
in directing immune responses through secretion of a plethora of factors. In CRC data 
regarding TAM and tumour progression are controversial. Of interest, in an experimental 
model of cancer TAM “re-educated” by CD40 ligand treatment, were found to be necessary to 
mediate antitumour activity, whereas tumour infiltrating lymphocytes (TILs) were irrelevant, 
supporting the hypothesis that TAM might mediate anti-tumour activity in certain conditions. 
The aim of this thesis was to study the prognostic significance of different populations (CD3
+
 
and FOXP3
+
 TILs and CD68
+
 TAMs) of immune cells in the tumour microenvironment, and 
their interactions with demographic and clinicopathological variables in a large dataset of 
stage II and III CRC patients. We first found that the cellular mediators of 
immunosurveillance seems to change along with the lymph-nodal involvement at diagnosis. 
Higher densities of TILs (both CD3
+ 
 and FOXP3
+
 cells) were associated with better 
prognosis among stage II CRC patients, but not in stage III. On the other hand, higher 
densities of TAM were associated with better prognosis only among stage III CRC patients, 
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but not in stage II. This data suggest that TILs mediate immunosurveillance in early stages of 
disease, while when the tumour has the ability to invade and spread to metastatic lymphnodes 
the mediators of surveillance seem to be macrophages. In detailed analysis, higher densities of 
TAM in stage III CRC were found to interact only with the variable 5-Fluoro-uracyl (5-FU) 
adjuvant chemotherapy treatment in predicting patients prognosis. We found that in stage III 
CRC patients, higher densities of TAM were associated with better survival only among those 
who received 5-FU chemotherapy. Moreover, the predictive effect of TAM in determining the 
efficacy of 5-FU chemotherapy showed significance only in microsatellite Stable (MSS) CRC 
patients. This is in accordance with the fact that microsatellite instability in CRC is a well-
known negative predictor of response to 5-FU chemotherapy. The positive predictive effect of 
TAM in stage III CRC prompted us to confirm our findings in the non-colonic metastatic site 
of those patients. The densities of TAM in metastatic lymphnodes retained a positive 
predictive effect in identifying patients obtaining a prognostic advantage with 5-FU 
chemotherapy treatment. Therefore, the antitumour effect of TAM in 5-FU treated patients is 
likely to be exerted mainly on tumour micrometastasis which spread from the primary site and 
may cause recurrence of CRC. Ultimately, our data are in accordance with clinical guidelines 
supporting the use of 5-FU as adjuvant treatment only in stage III CRC. This study shed basis 
for the future identification of the molecular basis and the functional role of TAM in 
mediating 5-FU tumour cell death in reliable experimental models of CRC.  
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Introduction 
 
Chapter 1. Colorectal Cancer  
 
1.1 Incidence and prevalence 
In the most developed countries in 2008, according to IARC (International Agency for 
research on cancer), Colorectal cancer (CRC) ranked second for cancer prevalence and third  
for cancer mortality when considering only men. While it was the third most frequent type of 
tumour and the second cause of cancer death among women. Advances in population 
screening made possible an early detection of precancerous lesions in patients. On this regard,  
data obtained from the Surveillance, Epidemiology, and End Results (SEER) program of the 
National Cancer Institute of the United States population from 1998 to 2008 revealed  a  
decrease in CRC incidence (-2.6%, -2.0%; for men and women respectively) and a decrease in 
CRC related mortality (-2.3%,-2.1%) 
1
. However, regardless of improvement in preoperative 
imaging, surgical technique and adjuvant CHT, nearly a third of CRC patients experience 
disease recurrence. About 20%–25% of patients with CRC retain a metastatic disease at time 
of diagnosis, and about 20%–25% of patients will later develop metachronous metastases 
after surgery resulting in relatively high overall mortality rates of about 40%–45% 2. On this 
regard, death from colorectal cancer parallels the incidence of metastatic disease and in 2008 
CRC was still responsible for 9% of all cancer related deaths in the United States. Surgery 
still represent the backbone of CRC treatment, as it maintains the greatest influence on 
survival. However, while curative surgery in CRC patients without distant metastasis at 
diagnosis is in general macroscopically radical, occult metastases are thought to be the source 
of disease recurrence 
3
. 
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1.2 Pathological Staging 
Cancer is not a single disease entity, cancer classification based on the tissue or organ where it 
arise was the first advance from considering all cancers as the same disease. Despite cancers 
have similar origins, clinical classification of cancers according to organ type and 
histopathological features helps clinicians in predicting cancer behaviour. Pathologists have a 
key role in the morphologic classification and final staging of surgically resected specimens 
and in the clinical diagnosis of patients with newly diagnosed CRC. The staging of resected 
CRC by pathologists remains the  cornerstone for the prediction of future disease relapse and 
progression. The current edition of the CRC staging system named Nodal Metastasis Tumour 
System (TNM) predicts patients prognosis and is currently the only standard method available 
to address patients to postoperative adjuvant chemotherapy (CHT).
4
 Despite many editions of 
TNM have been proposed by the years, those after the fifth edition didn’t provide significant 
advantage. Accordingly, the fifth edition of TNM is still the most used in Western countries. 
5
 
After many decades of utilization the current TNM staging system has now achieved near 
universal use. Developed by the cooperation between the International Union against Cancer 
(UICC) and the American Joint Committee for Cancer (AJCC), TNM is based on the extent 
of anatomic disease at the time of diagnosis, which is considered the main determinant of 
prognosis of colorectal cancer. This system was developed for CRC patients stratification 
according to the depth of tumour infiltration of the intestinal wall (T), the presence and the 
count of lymph nodes with metastases (N) and the presence and count of distant tumour 
distant metastasis(M).
6 
(a) clinical (cTNM) 
(b) pathological (pTNM); 
(c) post-surgical following neoadjuvant treatment (ypTNM) 
The depth of tumour invasion is indicated with the acronym pT: 
-pTis is a very early tumour lesion not invading underneath colorectal layers (in situ); 
-pT1 is a tumour lesion invading colorectal mucosa tissue layer; 
-pT2 is a tumour lesion invading colorectal muscular tissue layer; 
-pT3 is a tumour lesion invading pericolorectal tissue layer; 
-pT4  is a tumour lesion invading other structures or adjacent organs; 
The number of metastatic lymph-nodes is indicated with the acronym pN: 
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-pN0 is a tumour without clinical evidence of metastatic regional lymph-nodes; 
-pN1a is a tumour with clinical evidence of 1 metastatic regional lymph-node; 
-pN1b is a tumour with clinical evidence of 3 or less metastatic regional lymph-node; 
-pN2a is a tumour with clinical evidence of more than 3 metastatic regional lymph-node; 
The presence of distant metastasis is indicated with the acronym pM: 
-pM0 is a tumour without clinical evidence of  distant metastasis; 
-pM1 is a tumour with clinical evidence of  distant metastasis; 
(5th revision of the TNM staging system). 
 
Stages of disease are identified by subgroups of CRC patients according to T, N and M status. 
Stages classification according to the fifth edition of the American Joint Committee on Cancer 
(AJCC) staging systems is shown in the table 1.2.  
Table 1.2 CRC stages defined by the fifth edition of the American 
Joint Committee on Cancer (AJCC) staging systems. 
 
Stage Local invasion 
 
 
Nodal Metastasis Distant metastasis 
I T1 
T2 
N0 
N0 
M0 
M0 
II 
T3 
T4 
N0 
N0 
M0 
M0 
III Any T N1 M0 
IV Any T Any N M1 
 
TNM staging systems are designed to enable physicians to stratify patients in terms of 
expected predicted survival, to get information to select the most effective treatments, to 
determine prognoses, and to evaluate cancer control measures. To date TNM staging is the 
only method employed in clinical routine by physicians to predict CRC patients survival and 
to allocate patients to chemotherapy. Data from a study in 2004 by stratification of CRC 
patients in stages as defined by the AJCC fifth edition system from data obtained from a 
cohort study in 2004, 5-year colon cancer-specific survival was 93.2% for stage I, 82.5% for 
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stage II, 59.5% for stage III and 8.1% for stage IV 
6
. The log-rank survival analysis for the 
cohort used in this study is shown in the figure below 
6
. To date the most important prognostic 
marker of colorectal cancer survival is tumour cells detected in regional lymph nodes by 
histo-pathological examination
3
.  
Figure 1.2 Five year survival rate by stage I to IV according to 
American Joint Committee on Cancer fifth edition stages I-IV 
(Adapted from O'Connell 
6
). 
 
 
Despite the fact that TNM staging still remains the most important prognostic marker of 
survival and predictive marker of therapeutic response for CRC patients, clinicopathological 
staging lacks accuracy, and identification of all patients at greatest risk for disease recurrence 
or deriving optimum benefit from therapy for most CRC tumours is still not possible with this 
methodology. Accordingly, up to 30% of stage I and 50% of stage II patients develop 
recurrent disease. Stage III patients with radical cancer surgery including that metastasized to 
regional lymph nodes, exhibit recurrence rates of up to 70% 
3
. Differences in recurrence rates 
among studies in patients with node-negative and node-positive disease is likely an effect of 
down-staging of CRC with stage III or IV respectively, also caused by histologically 
misidentification of cancer cells. Imprecision in predicting CRC patients at risk reflects in part 
limitations inherent to the method 
3
. Microscopy has enhanced sensitivity, by improving the 
ratio cancer cells detection but pathologists typically reviews <0.01% of biopsied histological 
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tissue, producing sampling error, since more than 99.99% of available tissue is not examined 
and cancer cells do not distribute homogenously. Similarly, the outcome of CRC patients 
significantly differs between patients within the same histological tumour stage and the 
progression of advanced stage CRC can remain stable for years, while partial or full 
regression of large metastatic lesions can also occur spontaneously. An explanation for the 
limited accuracy in predicting outcome with traditional staging system lies in the estimation 
of tumour progression as an autonomous process without considering the evolution of the 
cancer as a balance of factors not histologically assessable. Therefore, the evidence that even 
histologically similar tumours arising from the same organ may have drastically different 
outcomes, prognosis and/or response to treatment gave rise to the hypothesis that CRC is a 
heterogeneous, multifactorial disease. In order to move to a more personalized cancer 
medicine there’s the need for molecular classification that might identify patients with 
common molecular patterns and progression abilities.  For this reason, the focus of CRC 
research moved from a clinical point of view to an understanding of its molecular basis.  
11 
 
1.3 Molecular carcinogenesis 
The colorectal carcinogenesis develop through an ordered and partially defined series of event 
named as “the adenoma-carcinoma sequence” and “multistep tumourigenesis” which takes 
years to decades to progress and which has its onset with the transformation of normal colonic 
epithelium with the formation of a small adenomatous polyp followed by formation of a 
larger polyp with dysplasia and then ultimately to adenocarcinoma. Multistep carcinogenesis 
was describe by proposing a model wherein the triggering mechanisms were found to be 
multiple genetic events occurring in gatekeeper and caretaker gene pathways,. In this model 
the sequential evolution of specific genetic alterations were associated with the occurrence of 
neoplastic phenotype in the colon and were required for tumour progression 
7
 . In their 
seminal paper Vogelstein and Fearon proposed and described a four-step sequential pathway 
that was declared to be sufficient to the development of cancer, while further genetic events 
were required for tumour progression. The first step was identified to be the inactivation of 
the adenomatous polyposis coli (APC) tumour suppressor gene, which is a component of the 
Wnt signalling pathway and was found to be the earliest molecular defect to cause adenoma 
progression. In larger adenomas and invasive cancer APC mutation was accompanied by a 
second step consisting in the activating mutations of KRAS which promoted adenomatous 
growth. The third step consisted in biallelic loss of chromosome 18q which allowed 
progression and the last step was proposed to be p53 inactivation which was able to triggers 
the transition to carcinoma. This sequence of molecular events was described 20 years ago, 
nowadays the multistep model has been implemented with the detection of mutations in 
additional target genes with a function in the oncogenic transformation, such as mutations in 
transforming growth factor–β (TGFβ) gene and PIK3CA pathways 8,9. This model predicts 
that at least seven distinct mutations are required 
7
. APC mutations are the necessary condition 
in adenoma formation in human and mouse models. In contrast, mutational activation of 
KRAS cannot initiate cancer in vivo, and only when combined with a mutation in APC mutant 
KRAS promote tumour progression. Genomic instability was recognized as an essential 
cellular feature that accompanies the acquisition of these mutations. Accordingly colorectal 
cancer is now classified in two main classes that represent genetic instability carcinogenesis 
pathways 
10
.  
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1.3.1 CIN pathway  
The first class, which represents about 85% of sporadic cases, have chromosomal instability 
(CIN)
10
. This term refers to gains or losses of whole or large portions of chromosomes that 
results in karyotypic abnormalities, namely allelic imbalances at several chromosomal loci 
and chromosome amplification and translocation, which together contribute to imbalances in 
chromosome named aneuploidy, sub-chromosomal genomic amplifications, and a high 
frequency of loss of heterozygosity (LOH) 
10
. Experimental evidence indicates that 
aneuploidy arises in CRC cancers because of CIN — when the rate of gains or losses of whole 
or large portions of chromosomes increases. CIN, is thought to enhance the acquisition of 
genetic changes that are required for tumorigenesis 
11
. However, it is still unknown whether 
CIN is the first event in tumorigenesis, and therefore precedes mutation of APC. Data suggest 
that chromosomal instability can be observed in adenomas, therefore it is thought to be an 
early event in carcinogenesis progression. The most common karyotypic abnormalities in the 
CIN pathway are loss of 5q, 8q, 17q, 18q allele together with the accumulation of mutations 
in oncogenes and tumour suppressor genes such as APC and K-ras 
12
.  
 
  
13 
 
1.3.2 MSI Pathway 
The second class of genomic instability, which comprise about 15% of sporadic CRC 
patients, have the phenotype of microsatellite instability (MSI). MSI represents a unique 
pathway for tumour development that does not involve LOH 
10
. Accordingly, MSI tumour 
cells had a tendency to be diploid and are characterized by the accumulation of single 
nucleotide mutations, gene length alterations named frame-shift mutations and base-pair 
substitutions that occurs in repetitive microsatellite and in short tandemly repeated nucleotide 
that are common in the genome, named microsatellites nucleotide sequences
13
. The most 
frequent errors associated with microsatellites are base–base mismatches that escape the 
intrinsic proofreading activity of DNA polymerases, and insertion–deletion loops, which are 
extrahelical nucleotides that form DNA hairpins. Microsatellite are usually located in non-
encoding regions, but they could also be included in regions of genes with functions of cell 
proliferation control or apoptosis. These nucleotides occur when the first nucleotide and 
template strand dissociate and incorrectly re-anneal in a microsatellite. DNA sequences of 
genes containing such microsatellites sequences were altered resulting in premature stop 
codons and frame-shift mutations that ultimately resulted in protein truncations and loss of 
function. The epiphenomenon of microsatellite instability is the loss of mismatch-repair 
(MMR) function which lead to the failure of repair activity of strand slippage within repetitive 
DNA sequence elements. The MMR system has the function to correct errors introduced in 
microsatellites and MLH1, MSH2, MSH6 and PMS2 are the principal proteins taking part in 
this task by their interaction as heterodimers. When the system works, MSH2 interacts with 
either MSH6 or MSH3 and MLH1 couples with PMS2, PMS1 or MLH3
14-16
. Mutations and 
epigenetic silencing in the above genes lead to an accumulation of errors in DNA, which 
results in MSI. In sporadic colorectal cancer with microsatellite instability, somatic epi-
genetic silencing blocks the expression of MLH1 by hypermethylation of its promoter 
11,13-16
. 
The MSI phenotype is strongly associated with mutations in specific oncogenes and tumour 
suppressor genes, especially BRAF and less to K-Ras in agreement with the fact that the latter 
mutation is mutually exclusive with the first 
10
. MSI is more common among stage II (~20%) 
than stage III (~12%) CRC, and is less frequent also in stage IV CRC (~4%). MSI tumours 
are characterised by proximal location, mucinous histology, poor differentiation, and 
lymphocytic infiltration 
17
. Different patterns of mutant genes can be seen in MSI vs. the CIN 
tumours suggesting that the underlying form of genomic instability in the cancer influences 
the susceptibility to and selection for specific mutations 
10
. 
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Chapter 2. Tumour associated inflammation 
2.1 Inflammation in cancer  
Rudolf Virchow 150 years ago was the first who described the presence of infiltrating 
leukocytes in tumours, and theorized that cancer arises at the chronic inflammation site.  In 
support of this has been later reported that chronic infections are associated with 15–20% of 
malignant cancers 
18,19
. Helicobacter pylori, hepatitis B and  C viruses, and the human 
papilloma virus has been established to be risk factors associated with gastric cancer, 
hepatocellular carcinoma, and cervical cancer, respectively. Moreover, smoking and obesity 
have been associated with an increase of 20% and 30% of risk of cancer respectively 
20
, which 
both can in turn trigger inflammatory responses in the lungs and liver, respectively, which is 
the cause of tumorigenesis promotion 
21,22
. According to such results and others, inflammation 
plays an important role in promoting cancer development , and recently inflammation has  
been included in the next generation of the criteria as a new ‘‘hallmarks of cancer” 23. Solid 
cancers are organ-like structures and their growth and development has been shown to be 
modified by the behaviour of recruited cells in the tumour microenvironment, which typically 
are bone marrow derived cells 
24
. Accordingly, along cancer progression the crosstalk 
between tumour cells and the microenvironment is crucial. Pro-inflammatory cytokines are 
released in the tumour microenvironment, and has been demonstrated that such molecules are 
very important for cancer development 
25
. Inflammation may predispose to cancer through 
enhanced cellular proliferation and mutagenesis, inability to adapt to oxidative stresses, 
promotion of angiogenesis, inhibition of apoptosis, and secretion of mediators that may 
promote tumorigenesis
25
. Large amount of experimental, epidemiological, and clinical data 
suggest that chronic inflammation is linked causally to cancer occurrence 
26
.  
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2.2 Inflammation in Colorectal Cancer 
Moving to intestine, chronic inflammation has been shown to be a risk factor of colorectal 
cancer (CRC) occurrence. Ulcerative colitis and Crohn’s disease, which are thought to be the 
two major types of inflammatory bowel disease (IBD), have been both associated with an 
increased risk of developing colitis associated colorectal cancer (CAC). Ulcerative colitis 
patients were found to retain a risk to develop CRC of 2% after 10 years, 8% after 20 years 
and 18% after 30 years of active disease 
27
. Interestingly, the relative risk of developing CRC 
was not changing when comparing patients who retain Crohn’s colitis with patients who 
retain ulcerative colitis of similar severity 
28
. The pathogenesis of IBD is thought to be related, 
in genetically susceptible individuals, to an excessive stimulation of the immune system 
directed to antigens of the gut microbiota and this series of events is thought to cause chronic 
inflammation 
29
. On this regard, general consensus is reached on the fact that chronic 
inflammation of the colon such as that observed during either UC or CD increases the risk of 
developing CRC. However, it is worth considering that IBD-related CRC, named Colitis 
Associated CRC (CAC) is estimated to be responsible for less than 2% of all CRC appearing 
annually 
30
. Moreover, further than inflammatory bowel disease the role of inflammation in 
sporadic colorectal cancer remains undefined from a clinical and an experimental point of 
view
31
. In colon the initial evidence for cytokine-regulated tumour promotion came from the 
studies in the mouse model of CAC 
32
.  However, according to Karin et al the same 
mechanisms might be applied to sporadic CRC 
25
. Among the most important inflammatory 
mediators, tumour necrosis factor (TNF)-α and interleukin (IL)-6 has been shown to activate 
nuclear factor NF-kB and Stat3, in turn NF-kB induces the expression of COX-2, IL-6, and 
TNF- α  25,33 34. CRC tumours and cell lines were shown to retain activation of NF-kB and 
Stat3 transcription factors which are thought to be essential components of inflammatory 
pathways 
35,36
. However, no activating mutations in NF-kB or STAT3 have been detected to 
date in colorectal or colitis associated tumours, this consideration is important to underline a 
likely activation of signalling pathways components upstream of such transcription factors or 
alternatively they might be activate in a paracrine or autocrine fashion
25
. Accordingly, these 
signalling pathways construct an inflammatory network in the tumour microenvironment, 
which plays an important role in tumour promotion 
33,34
. The most convincing clinical 
association between inflammation and risk to develop sporadic CRC comes from an old drug. 
Many robust epidemiological studies, both observational and randomized controlled studies, 
have revealed that regular use of non-steroidal anti-inflammatory drugs (NSAIDs) as for 
16 
 
example aspirin is associated with a lower probability to experience gastrointestinal cancer 
37-
39
. This effect is supposed to be mediated through abrogation of chronic inflammation. 
NSAIDs are drugs that specifically target cyclooxygenase COX-1 and COX-2 molecules 
which are known to be involved in inflammatory pathways
40
. Accordingly, many studies 
indicated that COX-2 and its downstream product, prostaglandin E2 (PGE2), play an 
important role in cancer development to promote inflammation and cell proliferation 
41
. On 
this regard, an epidemiological study from Chan which took advantage of more than 30 
thousands women demonstrated that those with very high plasma levels of TNFR-2 had a 
higher risk of developing CRC and the chemo-protective effect of aspirin was shown to be 
retained only among women with high TNFR-2 levels 
31
. This evidence is the most 
convincing to support the hypothesis that aspirin reduce risk of colorectal neoplasia through 
anti-inflammatory pathways. On the other hand, it is important to underline that the effect of 
aspirin on the survival after diagnosis of CRC is not clear, raising doubts on aspirin use as an 
agent for adjuvant therapy in CRC. On this issue, a recent paper from Ogino stated that 
regular aspirin use after CRC diagnosis had an impact on survival only among patients with 
mutated-PIK3CA tumour
42
. Mutations in PIK3CA (the gene encoding phosphatidylinositol-
4,5-bisphosphonate 3-kinase) are present in only about 15 to 20% of colorectal cancers 
42,43
. 
Therefore, NSAIDs protective effect in the progression of CRC seems to be retained only 
among subclasses of patients with peculiar molecular features, supporting a “tailored” or 
“personalized” chronic inflammation role to sporadic colorectal cancer pathogenesis from the 
onset to the recurrence and progression. Considering the heterogeneity of colorectal cancer 
evolution among patients, the complexity of the interactions between tumour cells and the 
various subtypes of innate and adaptive immunity make difficult to precisely define the role 
of different cell types, cytokines or growth factors in either promoting or containing cancer. 
Thus, the contribution of mediators of inflammation to cancer biology can’t be generalised, 
since they might retain different roles along progression of tumours with the same 
histopathology and arising in the same organ.   
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2.3 Immunoediting and cancer 
2.3.1.Immunosurveillance in experimental models 
As mentioned in the previous paragraph, inflammation is a complex physiological process, in 
the early 1990 the possibility to develop new genetic models of immunodeficiency 
readdressed the role of immunity in cancer. The idea of cancer immunosurveillance started 
with the evidence that INFγ was implicated in rejection of tumour transplanted in mice 44. 
Moreover subsequent studies revealed that by targeting INFγ receptor or Stat1, the 
transcription factor required for INFγ receptor signalling), or by inhibiting adaptive immunity 
with RAG-/- mice (without B, T and NK cells) were more susceptible to spontaneous tumours 
and to carcinogenesis induced tumourigenesis 
45,46
. According to Schreiber’s model 47, 
immunity has been shown to take part in cancer immune surveillance through different 
mechanisms. To eliminate viral infections which are potentially related to cancer and 
therefore suppresses virus-induced tumours; to eliminate pathogens which are thought to 
mediate an inflammatory microenvironment and thus might facilitates tumourigenesis if not 
killed; to eliminate tumour cells since new transformed epithelial cells often de-novo express 
ligands for receptors on innate immune cells and tumour antigens  that are recognized by 
immune receptors on lymphocytes of the adaptive immune system 
47
. The landmark principle 
of cancer immunosurveillance theory reside in the ability of cancer cells to express antigens 
that are not expressed by the normal tissue from which they arise. Seminal experimental 
models indirectly demonstrated the presence of tumour antigens which were named 
“transplantation rejection antigens” 48. The first of such experiments showed that mice 
exposed to chemical-induced tumours were immunized and therefore protected by following  
challenges with the same tumour 
48
. In 2001 a study from Shankaran revealed that only half of 
the tumours were growing when reimplanted in syngeneic immunocompetent mice if were 
arise and derived from carcinogen-treated immunodeficient mice, compared to tumours 
arising from immunocompetent mice 
46
. Tumours arising in immunodeficient mice were 
named “unedited” while those arising in immunocompetent mice were “edited” 46. Therefore 
immune system was able to shape tumour antigens content by selecting less immunogenic 
clones who might escape from immune system control and give rise to clinically relevant 
tumours. This evidence gave rise to the assumption that immune system has a dual role on 
cancer evolution, by both eliminating and promoting cancer. In 2002 Dunn and colleagues 
postulated the cancer immunoediting theory which proposed three phases of 
immunesurveillance: elimination, equilibrium and escape phase 
49
. In elimination phase 
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adaptive and innate immune systems interacts to detect tumour antigens and to eliminate it. 
The release of ligands that are expressed by dying tumour cells might bind to innate immune 
cells which in turn release cytokines that  facilitate tumour cell killing by adaptive immune 
cells in a coordinated activation of both cellular types. Different studies which took advantage 
of immunodeficient hosts for specific immunity subsets or cytokines and pathway effectors 
deficiency has proved that immunity requirements for cancer elimination are dependent on the 
specific tumour characteristics, its anatomical site of onset and its origin 
50
. 129/Rag2−/− 
mice developed more spontaneous epithelial tumours (of which 35% were gastrointestinal 
tumour and 15% were lung tumour) than mouse wild-type 
46
. In agreement with such 
statements, 129/Sv RAG2−/− mice that also lack STAT1, which is required for INFγ 
signalling, retained an earlier onset of disease and more aggressive, with the development of 
colon and mammary adenocarcinomas 
46
. Consistent with a role for the innate immune cells in 
cancer immunosurveillance, mice chronically depleted of NK cells displayed increased 
tumour incidence 
51
. Therefore both adaptive and innate immune responses were involved into 
elimination process. However, C57BL/6 β2microglobuline-deficient mice that lack NKT cells 
and many CD8+ T cells was shown not to increase tumour formation upon aging 
52
, 
suggesting that distinct lymphocyte populations may play distinct roles, if any, during cancer 
immunosurveillance of spontaneous tumours. Tumour cells which survive elimination phase 
may enter into equilibrium phase. In this phase immune system might shapes tumour cells 
immunogenicity by keeping them in a low number. The host immune system and tumour cells 
enter a dynamic balance, wherein powerful antitumor immunity contains, but does not fully 
eradicate, a heterogeneous population of tumour cells. Experimental evidence of this tumour 
latency comes from studies which shown that mice injected with low dose carcinogens had no 
macroscopic evidence of cancer 
53
. When T-cells (CD4 and CD8) or INFγ signalling were 
experimentally depleted by mAbs, tumours became visible at the site of injection. In contrast 
mAbs that deplete NKcells, block NK cell recognition (anti-NKG2D), or inhibit NK cell 
effector function (anti-TRAIL) failed to cause the appearance of growing tumours at the site 
of carcinogen injection 
53
. Consistently cells isolated from arising tumours were highly 
immunogenic and further characterization revealed that adaptive but not innate immunity was 
responsible for keeping tumour cells in a dormant state 
53
. This evidence separate equilibrium 
phase by elimination phase as the latter required the cooperation of both immune systems to 
work. The natural selection process occurring in the equilibrium phase results in the selection 
of immuno-edited tumour clones which acquired mutations that gave tumour cells immune 
evasion abilities. Edited tumour cells are those who gained the ability to evade immunity 
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control after a long selection process during equilibrium. In a process that might last many 
years cancer cells undergo stochastic genetic and epigenetic changes in order to generate the 
critical modifications necessary to evade both innate and adaptive immunological protection.  
Immune evasion occurs because a heterogeneous population of tumour cells changes in 
response to immune system selective pressure, wherein immune system contributes to tumour 
progression by a Darwinian selection of more aggressive tumour variants more prone to 
survive and to suppress the antitumor immune response
50
. In another perspective, immune 
evasion might occur as a result of host immune system impairment by external factors or by 
cancer ability to suppress immunity response. In the first option, loss of tumour antigens is the 
main driver of immune evasion and it occurs through different mechanisms, tumour cells can 
acquire defects in antigen processing and presentation pathways that facilitate evasion from 
adaptive immune recognition. MHC class 1 is the molecule that present  antigens to T cells, 
interference in INFγ pathway such as mutations and epigenetic silencing in INFγ receptor 
leads to insensitivity to its ligand and therefore the inability to increase MHC1 protein 
expression required for antigens presentation. On this regard loss of proteins involved in the 
MHC1 pathway machinery presentation such as TAP1 and 2 and B2microglobuline might 
affect tumour cells recognition by immune cells 
50,54
. In a different escape strategy, tumour 
cells might start expression of immune inhibitory ligands that avoid immune recognition or 
cytotoxic ability in order to generate an immunosuppressive environment. The occurrence of 
immunosuppression is concomitantly with tumour development by release from tumour cells 
immunosuppressive cytokines as VEGF, TGFβ and by recruiting T regulatory (T-regs) cells , 
macrophages and myeloid derived suppressor cells (MSDC)
50
. T-regs are CD4
+
 cells 
expressing FOXP3 transcription factor  and produce TGFβ and IL10 and expressing CTLA4 
50
. Tumours may also attract MSDC, which have the ability to recruit T-regs ,and tumour-
associated macrophages (TAMs) by producing IL-4 and IL-13. M2 macrophages can inhibit 
antitumor immunity through the production of TGF-β and IL-10 and can promote stromal 
development and angiogenesis through secretion of platelet-derived growth factor (PDGF) 
34
. 
Chronic inflammation has been clearly demonstrated to contribute to cancer initiation by 
generating genotoxic stress, cancer promotion by inducing cellular proliferation, and cancer 
progression by enhancing angiogenesis and tissue invasion. On this regard, Vesely and others 
suggested that there is overwhelming evidence that cancer immunity might exert also 
immunosurveillance that shouldn’t be seen as a mutually exclusive process with cancer 
inflammation but rather as potentially overlapping immune algorithms. For example 
inflammation participates in the cancer immunoediting process during the tumour escape 
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phase, when inflammatory cells and regulatory immune cells are recruited and activated by 
cancer-derived products to dampen antitumor immunity and subvert immune cells to promote 
cancer progression
50
.  
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2.3.5 Clinical evidences of immunoediting  
Many evidences suggest that cancer immunoediting is an alternative concept that integrates 
immune system roles in shaping cancer cells immunogenicity. Human immunodeficiency 
(AIDS) patients has been shown to have an higher risk of colon, lung, pancreas, kidney, head 
and neck and melanoma cancers 
50
. Moreover reports exist of patients receiving organ 
transplantation from the same donor and later developing the same tumour from which donor 
was diagnosed, treated and recovered 
55
. A plausible  explanation for this evidence is that the 
tumour cells were present in the donor, even though not clinically detectable, and were kept in 
a dormant state from donor’s immune system equilibrium phase. The transplant of such cells 
in an immunodepressed and naive host gave the ability to cancer cells to grow and kill the 
patients. Cancer immunoediting theory fits to progression of early stages of CRC not 
associated with CAC. In this case surgery can remove macroscopically detectable colon 
cancer burden by physical excision while adjuvant chemotherapy is administered by assuming 
that it will kill circulating tumour cells and micrometastasis which spread out the whole body. 
Such cells are not detectable by conventional diagnostic methods and are kept in a dormant 
state, while after many years they may give rise to metachronous metastasis which are the 
main cause of death in colorectal cancer. Immune system might play a role in this process by 
keeping not detectable micrometastasis in an equilibrium phase for many years, while the 
evolution of such tumour cells might give them the chance to escape immune system 
recognition and cause recurrence events. Adjuvant chemotherapy gives a survival advantage 
CRC patients, though its role on immune system micrometastasis recognition is still 
unknown.  
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2.4.Immune cells in colorectal cancer microenvironment 
2.4.1.Contribution to tumour microenvironment 
2.4.1.1 Tumour infiltrating Lymphocytes (TILs)  
In CRC immune cells infiltrates tumour stroma and thus take part in tumour 
microenvironment. The adaptive cells of immune system are represented by CD8
+
 CTLs and 
the CD4
+
 T helper lymphocytes. CD4
+
  T cells main function is to release cytokines, such as 
IL-2, TNFα and INFγ, by doing this T helper cells influence and promote stimulation of CTLs 
cells, on the other hand CD8
+
 T cells are able to produce perforin and granzyme B, which 
mediate the cytotoxic activity of CTLs on target cells 
56
. Therefore, CTLs have the ability to 
mediate identification of tumours and their specific elimination 
57,58
 . T-lymphocytes are also 
kept under control by a subpopulation of T- lymphocytes named T-regs which have the role to 
control immune responses 
59
. The transcription factor forkhead box protein P3 (FOXP3) is 
recognised to be a sensitive T-reg cell marker 
59,60
. T-reg cells are represented by different 
subpopulations but most studies detected T-reg cells as a population expressing CD4
+
 CD25
+
 
T cells markers of which the latter is a subunit of the receptor for the T cell-stimulating 
cytokine IL-2, and FOXP3 
59
. However, none of these markers is fully restricted to T-reg cells 
because CD25 and FOXP3 are also expressed by activated effector T cells
61
. According to 
Fridman, the antigen specificity of tumour-infiltrating T-reg cells has yet to be established in 
humans and for this reason T-reg cells may have different functions according to the type of 
tumour contexture, as they might block anti-tumour immunity or decrease chronic pro-tumour 
inflammation 
61
. T-lymphocytes recognition of antigens after immune response is kept at a 
higher activation level compared to the baseline. Activated T-lymphocytes have long life and 
are characterized by the expression of specific surface molecules and are more sensitive to 
stimulation than naïve T-lymphocytes. Such CTL cells phenotypically switch CD45 isoform 
from CD45RA to CD45RO 
61
. In a paper from Koch was functionally demonstrated for the 
first time activation and cytotoxic activity of CD8
+
 TIL and migration of CD4
+
 T helper cells 
that  was tumour specific in CRC tissues 
62
. Accordingly, in this study authors found a higher 
proportion of activated and cyto-toxically active CD8
+
 TIL in colorectal cancer compared 
with normal mucosa and the increased activation, the cytotoxic activity, and the functional 
reactivity of TILs were correlating with the presence of functional tumour antigen-reactive T 
cells in the blood and bone marrow. Moreover, they found that the proportion of activated 
TILs decreased significantly in higher tumour stage (from stage II through stage III to stage 
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IV), giving functional assessment of increasing immune evasion along with more advanced 
clinical histopathologically staging 
62
. In a study from Atreya authors proposed the proportion 
of activated CD8
+
 TILs is not the only relevant feature in mediating CTL antitumor activity, 
as their cytolytic abilities is determinant to mediate an effective antitumor activity 
63
. Authors 
demonstrated that eomesodermin, a T-box transcription factor involved in controlling the 
cytotoxic activity of CD8
+
 CTLs, is inversely correlated with the presence of lymph node 
metastasis at diagnosis in CRC patients 
63
. In accordance with these data a paper from Laghi 
group showed clinical evidence of cancer immunoescape along with the progression of CRC 
from stage II to III and thus along lymph-node metastasis. Accordingly CD3
+
 densities lost 
their prognostic abilities in advanced stage of colorectal cancer patients while CD3
+
 densities 
were a strong prognostic factor only in patients without local metastatic disease at diagnosis.  
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2.4.1.2 Tumour associated macrophages (TAM)  
It is generally accepted that in the majority of cancers TAM have a protumoural effect. TAM 
recruitment at the tumour site favours angiogenesis, and their secretion of chemokines 
stimulate proliferation and invasion of tumour cells 
64-69
. Macrophages play a key role in 
directing immune responses through secretion of a plethora of immune mediators such as 
cytokines, tumour necrosis factors alpha and beta, interleukins (IL-1, IL-8 and IL-10) and 
prostaglandins. Accordingly one of the early roles of macrophages is to release pro-
inflammatory cytokines . Moreover tissue macrophages are cells of the innate immune 
response capable of phagocytosis and antigen presentation 
70
. Macrophages are very versatile 
and plastic molecules which show different functional activities even opposite to each other 
depending on the local environment. Accordingly, diversity has emerged as a hallmark of 
mononuclear phagocytes and the same applies to the various forms of macrophage activation 
64-69
. During bacterial infections macrophages are the first defence of the host which arrange 
an acute inflammation to eliminate pathogens, afterward they become scavengers and in such 
configuration they have the function to heal the damaged tissue and to create new vessels and 
to recruit fibroblasts. In the attempt to oversimplify macrophages phenotypes Mantovani and 
coll. proposed two different polarization status named M1 and M2. M1 macrophages are the 
classical activated  ones and are stimulated by bacterial products and T helper type 1 
cytokines as for example INFγ. When macrophages are switched to M1 phenotype they start 
releasing immunostimulatory and inflammatory cytokines which enhance adaptive responses, 
reactive oxygen radicals (ROS) and nitrogen derivates (iNOS) which retain cytotoxic activity 
on bacteria and transformed cells 
64-69
. Macrophages exert cytotoxic activity by different 
mechanisms such as release of reactive nitrogen intermediates and members of the TNF 
receptor family. Antitumour activity of  M1 macrophages is exerted by negatively affecting 
vascular cells and activating coagulation which in turn cause tissue- and tumour-destructive 
reactions named hemorrhagic necrosis. M1 macrophages activates adaptive immunity to exert 
cytotoxic activity by releasing IL12 which support the formation of T-helper 1 (Th1) 
response. Differently, M2 type of macrophages differentiation is supported by tumour 
microenvironments rich in T helper type 2 cytokines as for example IL4 and IL13. It is 
important to underline that M2 macrophages has been shown to inhibit adaptive immune 
response while they acquire scavenging activity and release different growth factor necessary 
for tissue repair. Tumours might release the chemokine CCL2, which is a powerful activator 
of chemotaxis and thus attract monocytes to the site of tumour. Once in the tumour monocytes 
are differentiated to macrophages by M-CSF which is produced as well by CRC cells 
64-69
.  
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Analysis of different type of tumours revealed that TAM at the tumour site are mainly 
polarized to M2. It has been demonstrated that M2 macrophages in the tumour 
microenvironment facilitate tumour progression. In human cancers M2 macrophages revealed 
a typical gene expression profile, with over-expression of osteopontin, fibronectin, scavenger 
CD163
+ 
and mannose receptor. Moreover factors release by the tumour microenvironment 
such as M-CSF, PGE2, TGFβ, IL6 and IL10 retain the ability to differentiate macrophages to 
an M2 phenotype 
64-69
. In turn macrophages when polarized to M2 release epidermal growth 
factor (EGF), TGFβ, VEGF, metalloproteases (MMPs), cathepsins that promote tumour 
progression and increase expression of MHC class II. In CRC higher release of IL6 by 
macrophages induce IL10 production in tumour cells, which has been correlated with worst 
prognosis. Via secretion of immuno suppressive mediators, such as IL10, TGFβ and IDO, 
TAM retain the ability to suppress T-cell activation. As a source of TGFβ TAM in intestinal 
inflammation can directly induce T-regs differentiation which in turn can suppress CD8
+
 
mediated cytotoxicity likely contributing to immune evasion. On this regard TAM are thought 
to retain suppressive activity of adaptive responses by directly releasing T-cells inhibitory 
factors or indirectly by stimulating T-regs activity. According to Mantovani and colleagues 
TAM can also be associated with anti-tumour activities 
64-69
. However, the mechanisms 
behind the antitumor effects of TAM in different studies were not fully elucidated and could 
potentially be ascribed to the presence of classically activated M1 macrophages as it has long 
been known that M1 macrophages mediate extracellular killing of tumour cells. In this 
perspective, a paper from Forssell group interestingly pointed out that the degree to which 
macrophages exert their antitumorigenic abilities may partly depend on the possibility to get 
direct contact with tumour cells and a high macrophage to cancer cell ratio 
71
. In this study in 
vitro co-culture experiments revealed that a high ratio of macrophages to colon cancer cells 
inhibited cancer cell growth 
71
. Importantly, this effect was partially dependent on cell to-cell 
contact, on the other hand Boyden chamber cocultivation without macrophage-tumour cell 
contact promoted cancer cell spread. Accordingly, Forssell proposed that protumorigenic 
properties could be exerted by macrophages only when tumour cell were not in direct contact 
with macrophages. In accordance with this data was previously shown that glioma cells were 
killed by murine macrophages in a phagocytosis process only when transfected with the 
membrane but not the secreted isoform of macrophage colony-stimulating factor in 
72
. More 
significantly, it was recently reported that macrophage depletion in rats bearing colon cancer 
xenografts promoted enhanced cancer cell growth and impaired survival 
73
. Taken together, 
these results might suggest a role for macrophages in antitumor defense in colon cancer. 
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2.4.2 Prognostic value  
2.4.2.1 Undefined Lymphocytic infiltration, not characterized by CD antigen. 
A bunch of studies since late 60s have been reporting that an inflammatory cell response in 
CRC was recognised to confer an improved clinical outcome 
74-78
. The first report giving 
evidence of an association between a better CRC related survival and tumour infiltrating 
lymphocytes at the tumour periphery and at the tumour centre dated 1967 
74
. Lymphocytic 
infiltration was assessed by pathologists on haematoxylin and Eosin staining and was not 
informative on specific subpopulation of immune cells. A seminal paper from Jass in 1987 
proposed new criteria to classify immune lymphocytic infiltration determined by a semi-
quantitative quantification score 
77
. The selected variables were given weighted scores and the 
score range was divided to provide four prognostic groups. The prognostic classification of 
Jass was simple to use and was superior to staging by the method of Dukes because it placed 
twice as many patients into groups that provided a better prediction of clinical outcome 
77
. 
Accordingly, later studies confirmed lymphocytic infiltration as an predictor of survival 
independent of other histopathological characteristics 
79-84
. With the same methodology, in 
1990 a paper from Graham first described the presence of a “Chron’s like reaction” at the 
tumour site composed of discrete lymphoid aggregates with germinal centres 
85
. Such 
structures were later associated with better prognosis and higher lymphocytic infiltration. 
Later studies revealed that  lymphocytic infiltration and Chron’s like reaction was positively 
associated with MSI in CRC tumours 
84
. More recently, by taking advantage of 
immunohistochemistry it was possible to assess tumour infiltration of specific subsets of 
immune cells.  
Table 2.4.2.1 Summary table of studies reporting the associations between the in situ 
local inflammatory response and survival in colorectal cancer (Adapted from 
Roxburgh
86
) 
 
Immune cell infiltration 
Number of 
studies 
Studies reporting significant 
survival association 
Studies reporting  
no survival association 
Undefined Lymphocytic infiltration 39 36 3 
CD3+ expression 12 10 2 
CD4+ expression 5 1 4 
FOXP3+ expression 7 3 4 
CD45RO+ expression 8 8 0 
CD8+ expression 25 20 5 
CD68+ 13 9 4 
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2.4.2.2 Tumour infiltrating lymphocytes (TILs), classified by specific CD antigen. 
CD3
 
marker is employed for specific recognition of all subsets of T-lymphocytes, namely 
CTLs, T-helpers and T-regs.  As shown in above CD3
+
 and CD8
+
 antibodies has been 
employed as tumour markers and associated to CRC patients prognosis in many studies to 
date, of which 5 were contradictory while trends toward better survival was detected in two of 
those studies (reviewed in Roxburgh 
86
 and Table 2.4.2.1) . The first paper employing CD8 
marker was reported by Naito et al. which demonstrated that semiquantitative scoring of 
CD8
+ 
cells was independently associated with better survival 
87
. The first paper which 
analyzed CD3 and survival came out in 2001 and took in consideration only rectal cancers, at 
multivariate analysis CD3
+ 
density was not predicting outcome independently of TNM 
staging system 
88
. A later paper by Guidoboni et al. which took advantage of right sided colon 
cancers revealed that high infiltration of CD3
+
 was associated with MSI status and positively 
correlated with better survival independently of MSI status 
89
.  In the study from galon et al. 
authors stated that CD3
+
 density assessed by quantitative analysis was independently 
associated with better survival, but despite previous evidence, CD3
+
 density correlation with 
survival was found to be better than TNM staging, therefore suggesting to include CD3
+
 
density in clinical routine instead of TNM staging 
90
. On the contrary, in a recent and robust 
study by Nosho and co-workers in a large cohort of stage I-IV CRC, no survival relationships 
were reported for CD3
+
 T-lymphocytes at univariate analysis when measured at the epithelial 
neoplastic area, while this marker was significantly positively associated with prognosis when 
measured in the whole tumour tissue core or in tumour stromal areas 
91
. However, on 
multivariate analysis nor CD3
+
 or CD8
+
 cell densities were associated with better survival. 
The author explained this discrepancy compared to other studies by asserting that CD8
+
 cell 
density lost prognostic significance when adjusting statistical multivariate models for TNM 
tumour staging and CD45
+
 cell densities 
91
. Therefore the independent prognostic effect of 
CD8
+
 cells in other studies might be explained by the confounding effect of TNM tumour 
staging and CD45
+
 cells. Together with this evidence is important to underline that in a paper 
from Laghi et al. CD3
+
 cells were associated with better survival only in stage II CRC but not 
in stage III CRC 
92
. Here CD3
+
 TIL density was statistically interacting with TNM tumour 
staging in predicting prognosis and for this reason was not a stage independent predictor of 
survival. This paper raised the notion that CD3
+ 
TILs subsets are relevant to the fact that it can 
help in clinical decision making in the post-surgical management of stage II CRC. In this 
respect, the density of TIL subpopulations should be particularly evaluated in stage II CRC in 
which it might be of help in stratifying high- and low-risk patients in decision making for 
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allocation to chemotherapy. Importantly, this was the first clinical evidence of immunoescape 
in CRC, as the prognostic value of T-lymphocytes was lost in patients which retained a 
metastatic disease at diagnosis. Moving to CD4
+
 marker few studies reported relationships 
between tumour CD4
+
 T lymphocyte and cancer survival (reviewed in Roxburgh 
86
 and Table 
2.4.2.1). A report from Canna described a positive correlation with survival in patients with 
increasing general intratumoural CD4
+
 T-lymphocyte infiltration 
93
. CD45RO
+
 staining for 
memory T lymphocytes were assessed in different studies and were related to survival in 
colorectal cancer (Reviewed in Roxburgh 
86
 and Table 2.4.2.1). Higher densities of CD45RO
+
 
cells which were assessed at both the tumour centre and invasive margin were associated with 
better survival o patients prognosis. Pages et al in their study took advantage only of stage I 
and II (node negative) colorectal cancers and CD45RO
+
 which were measured at the tumour 
margin and centre was associated with better patients prognosis in both cases 
94
.  Moreover 
authors combined CD45RO
+
 and CD8
+
 T-lymphocytes and produced an ‘‘immune score’’ 
that was showed to be an independent prognostic factor 
94
. The paper from Nosho above 
described showed that CD3 densities were not predicting survival while T-lymphocyte 
subsets CD8
+
 CD45RO
+
 and FOXP3
+
 cells were all significantly related to better cancer 
survival at univariate analysis 
91
. When multivariate analysis was performed among all those 
immune markers included in the model CD8
+
 cells were not predicting prognosis 
independently of CD45 RO
+
 cells 
91
. Some studies took advantage of FoxP3
+
 cells to examine 
the prognostic value of T-reg cells in CRC patients (Reviewed in Roxburgh 
86 and Table 
2.4.2.1). Among them only two studies reported that FOXP3
+
 expression was an independent 
prognostic factor 
95,96
. The first study from salama group examined densities of FOXP3 in 
stage II and III CRC in intra-tumoral randomly chosen sections
95
, while the second study 
from Frey group found prognostic independence of FOXP3 only in MSS CRC
96
. In contrast, 
the study from Nosho stated that intraepithelial Foxp3
+ 
cells were not independent from 
CD45RO
+ 
cells when predicting outcome 
91
.  
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2.4.2.3 Tumour associated macrophages (TAM), classified by specific CD antigen. 
When considering TAM in CRC many studies have examined their predictive ability in 
colorectal cancer (Reviewed in Roxburgh 
86
 and Table 2.4.2.1). Nine studies reported 
significant positive correlations between macrophages either at the tumour margin or tumour 
centre and survival. In five studies the better associations with survival were observed when 
macrophages were assessed at the tumour invasive front. While four studies of modest 
patients cohort extent reported no relationships between CD68
+
 macrophages and survival 
(Reviewed in Roxburgh 
86 and Table 2.4.2.1). Forssell and Zhou proposed two different 
studies which took advantage of  446 and 160 patients, respectively and reported that higher 
counts of macrophages at the CRC tumour margin was an independent prognostic marker 
associated with better patient outcome and survival 
71,97
. However both studies took advantage 
of a semiquantitatively methodology for CD68
+
 cells infiltration assessment, which were 
evaluated by taking advantage of a manual count performed by pathologists which is 
subjected to operator’s estimation. Moreover the authors proposed a CD68+Hotspot value 
which was defined as the infiltration grade of the two highest view fields. Forssell suggested 
that a “vigorous macrophage response”  that authors proposed as “hotspot” at sites of ongoing 
invasion might be of help in interpreting the protective action of macrophages with respect to 
patient prognosis. In this study were included patients from stage I to IV and patients which 
also may have received adjuvant radiotherapy (before surgical treatment). According to the 
fact that only rectal cancer patients included in this study may had received neo-adjuvant 
radio and chemotherapy it is worth to underline that in this study CD68
+
 cells values were 
predicting better prognosis only among colon cancer patients 
71
. In the report from Zhou only 
patients with stage III or IV CRC patients which didn’t receive chemo or radiotherapy as neo-
adjuvant treatment were taken into consideration and moreover stage IV patients were 
correctly excluded from survival analysis
97
. Accordingly, clinical follow-up was only 
provided to stage IIIB patients, as patients with stage IV are a group with high heterogeneity, 
including solitary or multiple liver metastases, liver only or other sites involved with 
metastases; these variables affects the treatment protocols and eventually the response rate 
and prognosis. Interestingly, in this study CD68
+
 densities were lower in tumour stage IV and 
also in patients with synchronous compared to metachronous liver metastasis 
97
. This suggests 
that CD68
+
 densities were lower in stage IV regardless of disease progression and patients 
survival, therefore CD68 score in this study doesn’t seem appropriate to predict prognosis in 
patients with metastasis at diagnosis. Interestingly, in the study from Kang authors stated that 
intratumoral TAMs cause CRC cells to have a more aggressive behaviour, as CD68
+
 densities 
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were increasing along lymphnodal tumour metastasis in CRC patients 
98
. Differently from 
other studies on TAM, in this report CD68
+
 cell densities were quantitatively assessed, which 
is a more reproducible and objective method of measurement. However the authors didn’t 
provide any survival and prognostic associative data to support their assumptions and a mere 
association of higher recruitment of CD68 densities in CRC patients with lymphnodal 
metastasis compared to patients that were not metastatic is not indicative of  TAM pro tumour 
activities. Examples of CD68
+
 cells and CD3
+
 TILs and at the CRC invasive front and among 
tumour glands are shown in figure 2.4.2.3A. Examples of FOXP3
+cells in CRC Chron’s like 
reactions, the CRC invasive front and intratumoural space is shown in figure 2.4.2.3B 
 
Figure 2.4.2.3A Innate and adaptive infiltrating immune cells are detectable irregularly 
distributed in the tumour-stromal interface of the colorectal invasive front or among the 
tumoral glands. (Objective magnification, 10x). 
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Figure 2.4.2.3B. Forkhead box P3 (FoxP3)+ lymphocytes have been observed into 
Chron’s like reaction, at the tumor-stromal interface or among the tumoral glands. A 
clear nuclear immunoreactivity has been always found. (Objective magnification 20x 
and 40x).  
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2.4.2.4 Interplay with the type of genetic instability.  
Different studies have shown that MSI tumours are characterized by a stronger lymphoid 
reaction compared to patients with MSS molecular pattern. A Crohn’s like reaction consisting 
of lymphoid aggregates with germinal centres has been found to be predominant in 
microsatellite unstable tumours 
84
. Moreover, despite the fact that MSI is emerging as a 
biomarker of better prognosis, many studies showed that tumour infiltrating lymphocytes 
densities are independent of MSI when predicting better survival (Reviewed in Roxburgh 
86
 
and Table 2.4.2.1). Detailed analyses have shown that MSI-H CRC are characterized by 
tumour infiltrating immune cells predominantly cytotoxic and activated and moreover such 
tumours release mediators of target cell death which were found to be located in proximity of 
activated lymphocytes 
99
, suggesting that an higher lymphocytic reaction in MSI CRC might 
be one of the molecular pathways of this type of cancer involved in the longer survival 
compared to MSS patients . In a large study from Salama which employed tissue microarrays, 
MSI CRC was associated with higher densities of CD8
+
 and CD45
+
 cells, while FOXP3
+
 cells 
were not correlated with MS-status 
95
. In the same study, only FOXP3
+
 cells were 
independently associated with better survival. A large study from Frey et al. revealed that 
higher density of FOXP3
+
 cells was predicting prognosis only in MSS patients but not in MSI 
patients 
96
. In another large study from Nosho, which took advantage of intraepithelial 
measurements of immune markers, was revealed that in an adjusted analysis MSI patients 
were associated with a marked lower degree of FOXP3
+
 and higher densities of CD45RO
+
 
cells, while in the same model MSI was not correlated with the densities of CD3
+
 cells and 
CD8
+ 91
. This result suggests that lymphocytes infiltration in MSI CRC in this study was 
greatly composed of CD45RO
+
 and therefore of activated CTLs, while poor of Tregs. 
Moreover, in this study only CD45RO
+
 cells were independently predicting better survival. 
Moving to innate immunity, in a paper from Bauer was shown that infiltration of CD163
+
 
macrophages was significantly elevated in MSI-H compared to MSS CRC 
100
. The authors 
suggested that the high numbers of antigen-presenting cells such as macrophages in MSI 
tumours might be induced by MSI-H CRC-specific antigens and by the induction of 
frameshift antigen-specific immune responses commonly observed in such type of cancers. 
However the authors didn’t measure CD68 densities which is a pan-macrophages marker and 
didn’t took in account whether the burden of CD163+ cells was representing a subpopulation 
of macrophages infiltration in the tumour. It has been speculated and afterward suggested that 
frameshifts truncated peptides (FSP) that are aberrantly produced in MSI tumours might be 
immunogenic and for this reason might be presented to CTL
101-103
. This theory was proposed 
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as a biological explanation for the higher lymphocytic infiltration in such class of tumours 
since such peptides accumulate in the tumour cells and might be antigenic by eliciting 
immune response in the host 
101-103
. In vitro experiments with frameshift peptides 
demonstrated that such molecules are immunogenic and have the ability recruit T cells 
104,105
. 
However, later studies demonstrated that frameshift mutations have the ability to initiate 
nonsense mediated RNA decay system which cause RNA degradation of such microsatellite 
sequences when truncated and thus avoiding translation of FSP mutant proteins, for this 
reason it is still a matter of debate whether such FSP are generated in vivo 
106
. Moreover, MSI 
tumour microenvironment retain a pro-inflammatory cytokine milieu which is known to 
contribute toTh1 response 
107
, in line with an antitumoral immune response. Many studies 
demonstrated specific T cell responses directed against different MMR deficiency-specific 
antigens in individuals with MSI-H CRC 
101
. This was a convincing evidence that DNA 
sequences with frameshift mutations might elicit antigenic structures able to trigger antigen-
specific antitumor T cell responses. Genes with important functions in immunity regulation 
have been found to retain microsatellites sequences. In this regard TGFB receptor 2 gene, 
which is a major regulator of adaptive and innate immunity, retain an A10 repeat mutated in 
>90% of MSI-H CRCs 
8
. Frameshifts mutations of this repeat lead to an abrogation of 
TGFBR2-mediated signalling that lead to an increased growth rate of MSI-H tumours 
108
. At 
the same time was proposed that TGFB pathway perturbation in different cancers might be 
important for regulation of immunity in the tumour microenvironment 
109
. Accordingly, loss 
of tgfbr2 in MSI CRC might account for the increased lymphocytic reaction detected in the 
tumour site. Interestingly, it is worth to notice a paradox in the evolution of MSI 
tumourigenesis pathway, because frameshift mutations in MSI CRC while promoting tumour 
development by inactivating gatekeepers genes, at the same time they intrinsically make the 
tumour susceptible to recognition and elimination by the host’s immune system.  
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Chapter 3 Colorectal cancer response to 5-FU based treatment  
3.1 Chemotherapy in immunity driven tumour cell death  
The National Cancer Institute strategies to select conventional antineoplastic agents with the 
best ability to kill cancer cells of most solid tumours have been developed to date on murine 
immunodeficient host based on drugs ability to directly interact with cancer cells and thus to 
inhibit their growth or induce cell death 
102, 103
. However, this strategy completely neglect that 
the host immune system might have any effect or interaction on tumour eradication in the 
context of chemotherapy. Most anticancer treatments target rapidly proliferating cells without 
distinction whether they are immune system cells or tumour cells, since several cell types 
continuously proliferate in physiological conditions. For this reason conventional 
chemotherapy treatments are often associated with severe side effects which include 
myelosuppression, mucositis (linked to gastrointestinal toxicity) and alopecia. The 
immunosuppression caused by such treatments has not prevented oncologists to perform 
studies to assess whether immune system might have any role in the activity of conventional 
anticancer therapies. By taking advantage of different syngeneic solid tumours as in vivo 
models Apetoh and collaborators compared the ability of conventional anticancer treatments 
such as anthracyclines or oxaliplatin to promote tumour regression in immunodeficient versus 
competent mice. By taking advantage of this methodology, authors found that CD8
+
 T cells 
mice depleted or carrying the knockout of either INFγ or the INFγ receptor reduced the 
efficacy of chemotherapy treatments compared to immunocompetent mice 
110,111
. On this 
issue the group of zitvogel performed experimental studies to assess whether anticancer 
compounds might retain any ability to induce immunogenic cancer cell death. In the absence 
of any adjuvant therapy, inoculation of syngeneic CT26 tumour cells conditioned with sub-
lethal chemotherapy drugs could prevent tumour growth when live CT26 cell were 
rechallenged in immunocompetent Balb/c mice, while this therapeutic response was lost when 
treated CT26 cells were implanted in immunodeficient nude mice 
112
. Despite such evidences 
nowadays chemotherapy is still thought to kill cancer cells by apoptosis and thus in a non-
immunogenic fashion. Apoptotic cells express ligands that are different by those expressed on 
living cells and that are recognized by phagocytes. Phagocytosis signals expressed by 
apoptotic cells include calreticulin, oxidized low-density lipoprotein particles, 
thrombospondin-1-binding sites, C1q- or C3b/bi-binding sites, and mannose-binding lectins 
113,114
. These molecules are detected by phagocytic cells by recognition of scavenger receptors 
such as CD68 and CD36. Moreover, it has been reported that apoptotic cells can release 
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chemotactic signals which are known to recruit phagocytes, such as phospholipid 
lysophosphatidylcholine 
113,114
. Therefore it is reasonable to assume that massive apoptosis 
generated by chemotherapy agents might activate phagocitosis that might cross present 
tumour antigens to T-cells. Macrophages are the most prevalent antigen-presenting cells in 
tumours and in certain cases may account for about 50% of the tumour mass 
70
. Both DCs and 
macrophages have the ability to pick up tumour antigens for cross-presentation on MHC class 
I molecules 
115
. Accordingly, splenic marginal metallophilic macrophages (MMM) have been 
found to efficiently capture and transfer antigens exclusively to dendritic cells for cross-
priming cytotoxic T lymphocytes 
116
 . In this context it is important to consider that a recent 
paper from De Visser challenged the idea that adaptive system may increase chemotherapy-
mediated tumour cell death proposed by Zittvogel and colleagues
117
. In this study authors 
took advantage of two different genetic models of spontaneous murine breast cancer MMTV-
NeuT or K14cre; Cdh1flox/flox; Trp53flox/flox (FVB/N) crossbreeded with Rag2–/– mice. 
Cisplatin, oxaliplatin or doxorubicin ability to restrain the growth of mammary tumours was 
not changing in T and B cell deficient and immunocompetent mice 
117
. Therefore the absence 
of the adaptive immune system did not affect mammary tumorigenesis in both chemotherapy 
treated and untreated mice. This study employed spontaneous murine tumour instead of 
syngeneic ones and moreover they employed specifically adaptive immunity deficient models 
as controls instead of nude mice. Therefore understanding why the adaptive immune system 
does not contribute to chemoresponsiveness may yield to new strategies or new cellular 
mediators able to enhance chemotherapy-driven antitumor activity. 
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3.2 Predictive factors of 5-FU based adjuvant treatment responsiveness in 
stage I-III Colorectal cancers 
3.2.1 TNM staging and 5-FU based chemotherapy 
When excluding patients with distant metastatic spread of the disease, surgery has always 
been the primary treatment for patients from stage I-III CRC. In parallel, since the early 
1990s, 5-fluorouracil (5-FU) has been the mainstay of postsurgical chemotherapeutic 
treatment for patients with CRC in the adjuvant setting. Nowadays, almost all adjuvant 
chemotherapy regimens involve the use of 5-FU, typically in combination with leucovorin 
and more recently with oxaliplatin which retains better prognosis in CRC patients compared 
to 5-FU only based treatments 
118
. Since stage IV CRC retain a dismal prognosis and mostly 
doesn’t receive surgical treatment, chemotherapy is considered as a palliative medication 
among such patients which doesn’t retain a substantial benefit in terms of survival 119. In 
clinical practise administration of adjuvant chemotherapy in CRC patients is intended only for 
stage III CRC and stage II with poor prognostic features 
120
. The clinical guidelines suggest 
that only certain poor prognostic features in stage II CRC might recommend clinicians to 
consider adjuvant therapy 
121,122
. Poor prognostic features in CRC are: levels of preoperative 
carcinoembryonic antigen  more than 5 ng/mL, diagnosis of bowel obstruction or perforation, 
need for emergent operation, T4 local invasion, improper nodal resection (<12 lymph-nodes 
examined), or peritumoral lymphatic/venous invasion 
121,122
. However, there is no consensus 
that such clinicopathological tumour characteristics, are predictive of a good response to 
adjuvant chemotherapy 
121
. The QUASAR prospective trial, which is commonly cited, 
reported a an improved survival for patients with stage I to III colon and rectal cancer 
receiving adjuvant chemotherapy compared with surgery alone. However, when considering 
only stage II colon cancer subgroup of patients this study couldn’t prove any significant 
survival benefit of 5-FU based chemotherapy 
123
. A large meta-analysis including many 
clinical trials concluded that chemotherapy in patients with stage II disease provided an 
survival improvement that was statistically non-significant 
121
. Despite controversial and 
uncertain data, adjuvant chemotherapy is commonly administered to stage II patients with 
poor prognostic features. A recent paper on the issue from o’connor took advantage of about 
43’000 stage II and III colon cancer patients which were obtained retrospectively from the 
SEER registry and diagnosed from 1992 to 2005, stage II colon cancer were stratified in poor 
prognostic features 
124
. This epidemiological statistically robust paper revealed that patients 
with stage II colon cancer, even those with any of six identified poor prognostic features, do 
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not have a survival benefit from chemotherapy. The authors pointed out that the dataset 
included patients recruited for long period of time, and since adjuvant treatment regimen 
recommendations have changed during the period of the analysis many patients in this study 
population did not receive oxaliplatin, thus creating an heterogeneous distribution of 
chemotherapy regimens in the population studied, although all patients received 
chemotherapy 5-FU based 
124
. Accordingly, when considering only stage I-III CRC it is 
tempting to speculate that chemotherapy have a beneficial effect only at later stage of disease 
when tumour clones are more likely to have spread in to the body although not yet clinical 
detectable and thus immunoescape mechanisms may have selected tumour clones not 
detectable by immune system for their elimination. In this view I hypothesis that 
chemotherapy might cause alteration in tumour cells or de novo expression of molecules that 
might restore tumour cell immunogenicity and recognition by immune system.  It is important 
to notice that despite clinical evidences, the biological basis of discrepancies in terms of 
chemotherapy benefit along CRC progression are still unknown. The current need of valid 
experimental models which correctly reproduce CRC patients progression might explains at 
least in part this lack of knowledge.  
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3.2.2 Microsatellite-status and 5-FU based chemotherapy 
Different studies performed in vitro suggested a strong association between MSI-H and 
resistance to 5-FU chemotherapy. Koi and colleagues by taking advantage of hMLH1-
deficient HCT116 MSI CRC cell line, which is known to be resistant to 5-FU treatment, 
showed that chromosome 3 transfer in the same cell line which restored hMLH1 gene function 
also reinstated HCT116 cell line sensitivity to 5-FU chemotherapy 
125
. In another study the 
treatment of HCT116 MSI CRC cell line with the de-methylating drug 5-azacytadine, which 
restored transcription of hMLH1, also reinstated HCT116 cell line sensitivity to 5-FU 
chemotherapy 
126
. Moving to in vivo studies, the employment of ortothopic colon cancer 
xenografts confirmed that MSI tumours are not sensitive to 5-FU chemotherapy treatment 
127
. 
Moving to clinical studies, few reports gave no evidence of any predictive ability of MSI to 5-
FU treatment 
128,129
. However, a bunch of studies showed that MSI is a negative predictive 
marker of response to 5-FU. Such reports included randomized clinical trials
130,131
, 
retrospective case series 
132,133
, and a meta-analysis 
134
 and together provided evidence that 
CRC patients with MSI tumours had no survival increase from 5-FU adjuvant treatment and 
in the study from Ribic authors even suggested that 5-FU chemotherapy might worsen overall 
survival of MSI CRC patients 
130
. A pooled analysis of stage II and III CRC patients which 
included also patients from Ribic 
130
 study showed that MSI retained better prognosis 
compared with MSS only in the subgroup of chemotherapy untreated patients, while in the 
subgroup of CRC patients that received 5-FU adjuvant treatment  MSI didn’t retain any 
prognostic advantage compared to MSS and this evidence suggest that only MSS tumours had 
survival benefit by chemotherapy treatment 
131
. It is important to consider that in this study 
authors also pointed out that among MSS CRC patients 5-FU adjuvant chemotherapy was 
associated with better prognosis only in stage III subgroup of patients but not in stage II CRC. 
However, according to the low prevalence of MSI patients in the overall CRC population 
(about 10-15%) authors acknowledged that data produced in this study were based on a low 
prevalence of MSI that didn’t give proper statistical power to assess significant interaction 
effect 
131
. Ideally, predictive marker analyses should be conducted in studies that incorporate 
untreated control arms, however most studies do not meet this criteria. Nowadays it is 
clinically recommended that patients with stage II colon cancer which retain MSI should not 
receive 5-FU as adjuvant therapy 
131,135
. 
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9.3 Immune cells and 5-FU based chemotherapy 
As mentioned previously, many clinical studies measured immune densities in CRC and 
reported immune cells as positive prognostic factors. However, very few study assessed with 
efficacy the predictive impact of such infiltrates on the efficacy of conventional cancer 
therapies in CRC. In the context of immune infiltration chemotherapy treatment has important 
clinical effects as it might lead to myelosuppression, although speculation raised whether this 
effect might also give rise to suppression of inhibitory immune cell function and thus 
stimulating the peritumoral T cells to infiltrate and attack cancer cells 
136
. Alternatively, as 
explained previously, chemotherapy might induce an immunogenic cell death, which involves 
the de novo expression of antigens on tumour cells that might be immunogenic and thus 
providing immune cells antitumour abilities 
110-112,137
. Despite this strong experimental 
evidence most of the clinical studies which related immune cells presence and CRC prognosis 
did not reveal any predictive value of immune effectors. In the paper from Laghi, authors 
stated that the extent of CD3
+
 cells immunostaining did not affect the survival of the subset of 
stage III patients treated with fluorouracil adjuvant therapy 
92
. However, a study by Morris 
and colleagues reported that in an adjusted analysis, stage III colon cancer patients with 
higher densities of tumour infiltrating lymphocytes were gaining a survival advantage from 
adjuvant chemotherapy 
138
. It is important to notice that in this study detection of lymphocytes 
was obtained merely by pathological assessment. Moreover, was counterintuitive that in 
patients with low or high lymphocytes 5-FU chemotherapy was significantly associated with 
better survival in both subgroup of patients. To explain their results authors suggested that 
conventional chemotherapy might be an enhancer of antitumor immune responses and that the 
effects of chemotherapy might include the formation of a large amount of apoptotic tumour 
cells that enters the antigen presentation pathway. Authors also suggested that chemotherapy 
could also create lymphopenia as a side effect of such treatment, and in this phase immune 
system might be more receptive to the breaking of tolerance and thus stimulating their 
recognition and elimination of tumour cells. On this issue another study from Halama 
analysed immune infiltration and prognosis in stage IV CRC patients that received palliative 
chemotherapy treatment. In this study immune infiltration at the border with hepatic 
metastases was predicting better prognosis in CRC patients that received palliative 
chemotherapy and also included "technically nonresectable" liver metastasis 
139,140
. It has to 
be considered that the study employed a low number of patients with a dismal prognosis and 
very importantly lacked of a control “arm” of untreated patients. In this regard it is important 
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to notice that immune infiltrate in CRC of stage IV primary tumour has been found to be 
scarce 
141
, since this subgroup of CRC retain colorectal metastases in the liver and a dismal 
prognosis, the low immune infiltration might be an effect of immunoescape 
142
. Moreover, it 
is worth to consider that surgery in such patients is unlikely to be radical in the metastatic site. 
However, according to Fridman and colleagues at this late stage of disease an immune control 
of the neoplastic disease may still persist, although in very rare cases retaining a relatively 
favourable prognosis 
142
.In a study from Prall authors reported that the prognostic positive 
association with high CD8+ infiltration was more significantly marked in stage III CRC 
patients who received adjuvant chemotherapy treatment compared to the whole cohort of 
patients that included also those who were only treated by surgery 
143
. However, also in the 
whole cohort of patients a significant association with better prognosis and higher densities of 
CD8
+
 cells was reached 
143
. Thus, there’s some clinical suggestion that the amount of immune 
infiltrate before chemotherapy may have an impact on the efficacy of the treatment of 
colorectal cancer. 
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Material and methods 
Patients cohort 
Tissue specimens were taken from consecutive patients who underwent radical surgical 
resection for pT3 or pT4 colorectal cancer (CRC) at the Humanitas Clinical and Research 
Center, Rozzano, Milan, Italy, from January 1997 to November 2005. Patients’ demographics 
and pathological data were available from the Institutional Intranet. To investigate the 
occurrence of patient relapse, tissues from patients with pT1 or pT2 colorectal cancer, who 
have a very low risk of progression, and tissues from patients with perioperatively detected 
metastases were excluded. Patients who underwent neoadjuvant radiotherapy for rectal cancer 
were excluded from the study, because of the possibility of interference with the assessment 
of the local immune response. Investigators who were blinded to the results of the 
morphological analysis performed a clinical database. The absence of metastasis at diagnosis 
was assessed in all patients by combining histopathological findings, surgical records and 
perioperative imaging. The observation period started immediately after surgical procedure. 
To exclude postsurgical tumor recurrences, thoraco-abdominal computed-tomography (CT) 
abdominal ultrasonography, and chest radiography, were done according to common 
protocols for surveillance. Microsatellite status was screened preliminarily for all cancers 
included in the study by testing instability at mononucleotide repeats, as previously described 
17
. Ethics Committee of the Humanitas Clinical and Research Center approved the study, and 
written informed consent was obtained by the referring physician, at the time of surgery by 
each patient.  
Immunohistochemistry 
Formalin-fixed, paraffin-embedded, 2-μm thin sections of tumor were deparaffined and 
exposed to an antigen-retrieval system before being incubated with specific monoclonal 
antibodies raised against CD3 (dilution 1:50, clone F7.2.38, Dako, Italy), CD68 (dilution 
1:200, clone KP-1, Dako, Italy), FOXP3 (dilution 1:100, clone 236/E7, Abcam, Cambridge, 
UK), or with mouse IgG (Dako, Milan, Italy) as negative controls. Endogenous peroxidase 
was blocked with 3% hydrogen peroxide for 10 min at room temperature. Primary antibodies 
were applied for 1 h at room temperature. Reactive sites were identified by exposure to a 
MACH 4 Universal HRP-Polymer (Biocare, Space Import-Export, Italy) for 30 min at room 
temperature. Immunoperoxidase staining was then obtained by using diaminobenzidine as a 
chromogen (DAB
+ 
chromogen X-50, ChemMate, Dako Cytomation, Carpinteria, CA, USA). 
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The slides were subsequently counterstained with haematoxylin (Harris Hematoxylin, 
DiaPath, Microstain Division, Martinengo, Bergamo, Italy).  
Computer assisted image analysis 
Slides were digitized using a computer-aided image analysis system (Olympus DotSlide, 
Olympus, Italy). Assessment of CD68
+ 
TAM, CD3
+
 and FOXP3
+
 TILs density was 
quantified. An expert pathologist, who was blinded to any patient clinical data, selected three 
randomly selected non-contiguous and not overlapping microscopic areas located at the 
tumour invasive front, on tissue sections previously immunohistochemically treated with anti- 
CD68
+ 
TAM, CD3
+
 and FOXP3
+
 TILs antibodies. In each selected area, the cancer tissue had 
to represent approximately 50% of the entire microscopic field. To measure the extent of 
CD68
+ 
TAM, CD3
+
 and FOXP3
+
 TILs immunoreactivity, we used a computer-aided image 
analysis system with ad-hoc software able to discriminate the immunostained area on the 
basis of red, green, and blue (RGB) colour segmentation, and to calculate the per cent 
immunoreactive area as a fraction of the total area digitally captured (figure 1 Material and 
methods). For each histological section, the mean values obtained in three different regions 
were calculated and used for the subsequent statistical analysis as previously described from 
our group 
92
. Results from each of the three selected area were fairly homogenous in most 
tumours (data not shown), showing a good concordance among the three measurements. 
Examples of increasing CD68
+ 
TAM, CD3
+
 and FOXP3
+
 TILs IRA% are shown in 
supplementary appendix Figures 6 to 8. 
Metastatic Lymph-nodes 
In addition to the primary tumour tissues specimens we also obtained matched tissue 
specimen from metastatic lymph-nodes of 135 out of 209 stage III CRC available in our 
institution. The tumour area in the lymph-node had to be sufficient to select three fields of 
interest not overlapping to be stained for CD68 with the same methodology we employed for 
the primary tumour. In addition, the immunoreactive area was quantified with the same 
methodology previously described for the primary tumour. A representative image of an 
immunoreactive surface covered by CD68+ cells in a whole partially metastatic lymph-node 
is shown in appendix figure 9. 
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Figure 1 Material and methods. A computer-aided image analysis was used for quantifying 
infiltrating cells at the tumor front of invasion in primary colorectal cancer tissues. Tissue 
sections were treated with antibodies raised against CD68, CD3 and FoxP3, and subsequently 
three not-overlapping and not-contiguous fields were chosen for each cell-type at the tumour 
invasive front and digitized (A). The immune-reactive surface covered by the infiltrating cells 
was specifically and automatically selected on the basis of the RGB color segmentation (B). 
The immune-reactive surface was automatically obtained by the ratio between the 
immunoreactive surface area and the unstained tissue surface (C). Each patient is 
characterized by a unique value, for each cell-type, given by the mean values of the three-
fields randomly chosen at the tumour invasive front. In the present study has only been 
evaluated the cells infiltrating the tumor-stromal interface, with a ratio of nearly 1:1 between 
tumoral and stromal compartments. 
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Statistical analysis. 
The association between the extent of CD68
+ 
TAM, CD3
+
 and FOXP3
+
 TILs, patient’s 
baseline characteristics and tumour features was estimated by linear regression analysis. The 
distribution of immune cells densities in CRC at the tumor invasive front we studied was not 
resembling a normal one, but had a tendency to be skewed toward low values. For this reason, 
we represented the distribution of each immune cells type with categorical values in order to 
generate a qualitative interpretation to score data. A Cox proportional hazards model was 
developed to assess the role of CD68
+ 
TAM, CD3
+
 and FOXP3
+
 TILs density and other 
clinico-pathological features, in predicting the occurrence of disease specific survival (DFS). 
The detection of tumour recurrence or death was computed from diagnosis until data were 
censored on May 30, 2010. Recursive partitioning was referred to as CART analysis that was 
also used to identify optimal cut points in the data. The default tree was generated from the 
unmanipulated recursive partitioning CART algorithm. The partitioning of patients into 
groups with different prognosis using clinical variables available generates a tree-structured 
model that can be analysed to assess its clinical utility. Each tree’s structure depended on the 
selected split value of the chosen variable. CART analysis is inherently non-parametric and 
no assumptions were made regarding the underlying distribution of values of the predictor 
variables. Thus, CART can handle numerical data that are highly skewed as it is the case of 
immune cells distributions. Differences in median values of CD68
+ 
TAM, CD3
+
 and FOXP3
+
 
TILs density between subsets of CRC and according to DFS were tested by the Mann–
Whitney U test and by Cuzick's trend test. Kaplan-Meier curves of DFS and DSS were 
plotted, while log-rank test was used to compare the curves of each subgroup of CRC 
patients. The mean follow-up period was 4,66 years (SD = 2.58 years) for DFS. The mean 
follow-up period was 5.13 years (SD = 2.25 years) for DSS. A time-dependent receiver 
operating characteristic (ROC) curve was constructed to define the optimal cut-off value of 
CD3 and FOXP3 immunoreactive TILs area for predicting patients relapse in stage II cancers. 
A time-dependent receiver operating characteristic (ROC) curve was constructed to define the 
optimal cutoff value of CD68 immunoreactive TAM area for predicting patients relapse in 
stage III and stage III MSS cancers that received 5-FU adjuvant treatment (Supplementary 
appendix figure 1 to 5). For each test, only two-sided P values lower than 0.05 were 
considered statistically significant. To test whether CD68
+
, CD3
+ 
and FOXP3
+ 
immune cells 
abilities to predict CRC patients prognosis might be modified by any variables we assessed, it 
is highly relevant to assess statistical interaction effects. Accordingly, by entering into a 
logistic regression model the categorical densities of immune values, each of the variables we 
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assessed and a product term consisting of the multiplication of the variables included in the 
model we tested any statistical interaction when predicting the risk of patient’s outcome. All 
the analyses were done using Epi Info (Version 3.4.3), StatsDirect Statistical software 
(Version 2.5) and GraphPad Prism software (Version 4.1).  
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Results 
Chapter 4. Densities of CD68+, CD3+ and Foxp3
+
 immune cells in 
the primary tumour 
4.1 Distribution of CD68
+
, CD3
+ 
and Foxp3 
+ 
immune cells immunoreactive area at the 
tumour invasive front and their correlation with clinicopathological features at the time of 
surgery. 
The percentage of immunoreactive area (IRA) calculated represented the density of each 
population of immune cells in the selected areas. However, the definition of density as the 
relationship between the numerical count of cells and the tissue surface on which they are 
distributed, is not respected. In fact, IRA has been calculated as the area occupied by the 
immune cells for each marker studied, as compared to the whole image of stained tissue. 
Given that an accurate optical count of immune cells was not feasible in the presence of 
agglomerates, adjacent cells or long cellular bodies, as it is the case for macrophages, we did 
not make the attempt to convert area values into number of cells. The distribution of densities 
of each immune cell population did not resemble a normal one, but was skewed toward low 
values. We performed the analysis of immune cells densities in 425 CRC patients, with stage 
II and stage III. In appendix table 1 are shown the distribution of patients according to 
demographics, clinical and histopathological variables that we took in account. In the entire 
population of CRC patients the densities of CD68
+
TAM, CD3
+ 
and Foxp3
+
TILs
  
we studied 
ranged from 0% to 44.99%, from 0% to 20.04% and from 0% to 5.70% respectively. The 
median value of the distribution of CD68
+
TAM, CD3
+
TILs
 
and Foxp3
+
TILs densities in the 
overall population of cancers was 4.12%, 2.33% and 0.37% respectively. The first quartile 
and the third quartile of CD68
+
TAM, CD3
+
TILs
 
and Foxp3
+
TILs densities was 1.54% and 
9.61%, 0.92%  and 5.78%, 0.13% and 0.68% respectively. The densities of CD68
+
 TAM were 
the highest at the tumour invasive front among the population of CRC patients we studied 
(Figure 1). TAMs at the tumour invasive front represent the principal and prevailing 
population compared to TILs.  
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Figure 1. Distribution of CD68
+
TAM, CD3
+
TILs and Foxp3
+
 TILs densities at the 
tumour invasive front in the overall CRC population studied.  
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The relationship at uni and multivariate analysis between percentage of IRA of each immune 
cell population, demographics and histopathologic characteristics of patients recruited in this 
study is shown in table 2-4. CD68IRA% distribution was not changing according to the type 
of genetic instability and other CRC features (table 1).  
 
Table 1.  CD68-Immunoreactive area  (IRA, % of microscopic field) at the  Invasive 
Margin of 425 Stage II and III Colorectal Cancers.  
 
     
  Median 
Value 
2
nd
-3
rd
 quartile 
Univariate* 
 P 
     
Patient Age °  
<68 yrs 4.06 1.26 -   9.75 
0.83 
≥68 yrs 4.20   1.81 - 9.88 
     
Patient Gender 
Male  3.51 1.65 -   9.79 
0.98 
Female 4.49 1.29 -   9.45 
     
Microsatellite Status 
MSS 4.12 1.65 -   9.75 
0.98 
MSI 4.18   1.10 - 10.81 
     
Tumor Site 
Colon Dx 3.94 1.45 -   8.48 
0.12 Colon Sx 3.56 1.17 -   9.93 
Rectum 5.72   2.65 - 10.59 
     
Tumor Stage 
II 4.33 1.58 - 10.19   
0.18 
III 3.67 1.41  – 3.67 
     
Tumor Grade 
G1/G2 4.28 1.64 -   9.89 
0.09 
G3 2.09 1.16 -   8.21 
     
Tumor Cell Type 
ADC 4.27 1.66 -   9.77 
0.18 
Variants 2.31 0.37 -   8.59 
     
Vascular Invasion 
No 4.14   1.39 - 10.02 
0.34 
Yes 4.03 1.68 -   9.34 
     
5-FU Adjuvant Therapy     
Stage II 
No 4.29 1.19 – 11.79 
0.98 
Yes 4.37 2.20 –   9.66 
 Stage III 
No 3.47 1.96 –   6.63 
0.88 
Yes 3.95 1.24 –   9.79 
     
 
 *   Linear Regression Analysis.  “CD68-IRA%“ was entered as a dependent, continuous 
variable.  
  
 °   Age entered as a continuous variable   
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Moving to T-lymphocytes we found that CD3
+
 densities were significantly increasing in CRC 
patients with MSI compared to those with MSS, thus confirming data in the literature (Table 
2). Patients with CRC located in the right colon retained an high CD3IRA%, although this 
result was dependent by MSI status since MSI patients are more likely to occur in the right 
colon (data not shown).  
 
Table 2.  CD3-Immunoreactive area  (IRA, % of microscopic field) at the  Invasive 
Margin of  425 Stage II and III Colorectal Cancers.  
 
      
  Median 
Value 
2
nd
-3
rd
 quartile 
Univariate* 
 P 
Multivariate*  
P 
      
Patient Age °  
<68 yrs 2.42 0.89 -   6.11 
0.07  
≥68 yrs 2.17    0.92 -   5.69 
      
Patient Gender 
Male  2.24 0.89 -   5.16 
0.37  
Female 2.55 1.02 -   6.12 
      
Microsatellite Status 
MSS 1.94 0.83 -   5.03 
  <0.001 <0.001 
MSI 5.69 2.47 -   10.88 
      
Tumor Site 
Colon Dx 3.38 1.13 -   7.40 
  <0.001  Colon Sx 1.96 0.94 -   5.46 
Rectum 1.72 0.62 -   3.34 
      
Tumor Stage 
II 2.41 1.01 -   6.09 
0.30  
III 2.24 0.87 -   5.59 
      
Tumor Grade 
G1/G2 2.21 0.89 -   5.69 
0.20  
G3 3.24 1.02 -   5.93 
      
Tumor Cell Type 
ADC 2.34 0.91 -   5.73 
0.66  
Variants 2.32 0.66 -   5.80 
      
Vascular Invasion 
No 2.37 0.89 -   5.16 
0.12  
Yes 2.40 1.02 -   6.12 
      
5-FU Adjuvant Therapy      
Stage II 
No 2.33 1.01 -   5.80 
0.67  
Yes 2.56 1.01 -   6.13 
 Stage III 
No 2.04 0.86 -   5.35 
0.18  
Yes 2.32 0.87 -   5.93 
      
 
*   Linear Regression Analysis.  “CD3-IRA%“ was entered as a dependent, continuous variable.  
  
 °   Age entered as a continuous variable   
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Moving to T-Reg lymphocytes, FoxP3IRA% was significantly lower in MSI patients 
compared to MSS patients, independently from other variables studied (Table 3). Thus, with 
respect to TILs MSI was positively associated with high CD3
+ 
densities, and negatively with 
low FoxP3
+
 densities.  
 
Table 3.  Foxp3-Immunoreactive area  (IRA, % of microscopic field) at the  Invasive 
Margin of  413 Stage II and III Colorectal Cancers.  
 
      
  Median 
Value 
2
nd
-3
rd
 quartile 
Univariate* 
 P 
Multivariate*  
P 
      
Patient Age °  
<68 yrs 0.38 0.18 -   0.80 
0.54 
 
≥68 yrs 0.32    0.10 -   0.61  
      
Patient Gender 
Male  0.35 0.11 -   0.64 
0.20 
 
Female 0.38 0.16 -   0.73  
      
Microsatellite Status 
MSS 0.39 0.16 -   0.73 
  0.002 0.01 
MSI 0.21    0.00 -   0.46 
      
Tumor Site 
Colon Dx 0.35 0.12 -   0.61 
0.43  Colon Sx 0.34 0.12 -   0.80 
Rectum 0.40    0.20 -   0.71 
      
Tumor Stage 
II 0.34 0.12 -   0.62 
0.11 
 
III 0.38    0.14 -   0.73  
      
Tumor Grade 
G1/G2 0.37 0.14 -   0.70 
0.27 
 
G3 0.31    0.10 -   0.51  
      
Tumor Cell Type 
ADC 0.38 0.16 -   0.70 
  0.004 0.03 
Variants 0.14    0.00 -   0.41 
      
Vascular Invasion 
No 0.38 0.14 -   0.69 
0.12 
 
Yes 0.31    0.10 -   0.54  
      
5-FU Adjuvant Therapy      
Stage II 
No 0.32 0.08 -   0.61 
0.33 
 
Yes 0.37    0.15 -   0.68  
 Stage III 
No 0.26 0.10 -   0.57 
0.44 
 
Yes 0.42    0.20 -   0.80  
      
 
*   Linear Regression Analysis.  “Foxp3-IRA%“ was entered as a dependent, continuous variable.  
  
°   Age entered as a continuous variable   
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Table 4 shows linear regression coefficients between adaptive and innate immune densities. 
CD68IRA% was significantly increasing in patients with higher densities of CD3IRA% 
(P<0.001) and FOXP3IRA% (P=0.009), independently by other variables studied. Therefore, 
the recruitment of CD68
+
 TAM in the primary tumour positively correlates with the 
recruitment of both CD3
+
 and Foxp3
+ 
cells at the tumour invasive front. Differently, 
CD3IRA% did not correlate with the density of Foxp3IRA% (P=0.24) (Table 4).  
 
Table 4.Correlation between tumour infiltrating immune 
cells at the tumour invasive front in 413 Stage II and III 
Colorectal Cancers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
   CD68IRA%  CD3IRA%  FOXP3IRA% 
        
        
CD68IRA% 
  -  r=0.21  r=0.12 
  -  p<0.001  p=0.009 
        
CD3IRA% 
  r=0.21  -  r=0.05 
  p<0.001  -  p=0.24 
        
FOXP3IRA% 
  r=0.12  r=0.05  - 
  p=0.009  p=0.24  - 
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4.2 CART analysis of densities of CD68
+
, CD3
+ 
and Foxp3 
+
immune cells at the tumour 
invasive front to explore their correlation with patient’s outcome. 
By taking advantage of CART methodology we aim to test the ability of CD68
+
, CD3
+ 
and 
Foxp3
+  
immune cells densities in predicting disease progression by splitting such continuous 
distributions into subsets identified by an attributed threshold value. This process is repeated 
on each derived subset in a recursive manner (i.e. recursive partitioning). The recursion is 
completed when splitting no longer adds value to prediction. CART was performed by 
including in the analysis all the demographics, clinical and histopathological variables that we 
assessed and the densities of CD68
+
, CD3
+ 
and Foxp3
+  
immune cells. A default tree was 
generated by allowing the CART program to determine the variable with the optimal first split 
(Figure 2). The results for trees generated on 425 samples indicated that TNM staging was 
chosen as the initial split with a percentage of patients developing disease progression of 
34.9% for stage III (n=216) and 14.9% for stage II (n=209) CRC (Figure 2). The next split 
node showed that among stage II CRC patients, the densities of Foxp3
+ 
TILs 
 
and then 
CD3
+
TILs
  
immune cells were selected by CART analysis, as a predictor of patient’s outcome 
at an optimum cut-off value of 1.86% for CD3IRA% and 0.23% for FOXP3IRA% (Figure 2). 
In stage II subset of patients, densities of FOXP3IRA% below the value of 0.23% (n=85) 
identified CRC with a percentage of disease recurrence of 28.2%, while patients with 
densities of FOXP3IRA% in the tumour higher than 0.23% (n=131) had a percentage of 
disease recurrence of 6.1%. Therefore, densities of FOXP3IRA% were selected by CART 
analysis as a best predictor of disease relapse among stage II CRC. Similarly, in the next split 
densities of CD3IRA% below 1.86% identified CRC with a percentage of 39.1% of disease 
recurrence, while patients with densities of CD3IRA% higher than 1.86% selected patients 
with a percentage of disease recurrence of 14.3%. In stage III CRC node a cut-off value of 
12.13% for CD68IRA%, between the variables analysed, was found by CART analysis to be 
the optimal split to discriminate patient’s progression (Figure 2). Accordingly, a higher 
(>12,13%) density of CD68
+
 TAM identified patients (n=35) with a percentage of disease 
progression of 14.3% while patients with a lower (<12.13%) density of CD68
+
 TAM (n=174) 
had a percentage of disease recurrence of 39.1%. (Figure 2) 
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Figure 2. CART hierarchical recursive tree analysis in the overall CRC population 
studied.   
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4.3 Densities of CD68
+
, CD3
+ 
and Foxp3 
+ cells at the tumour invasive front and patient’s 
outcome  
As shown in table 5 we performed univariate and multivariate Cox regression analysis of the 
densities of CD68
+
, CD3
+ 
and Foxp3 
+
 immune cells. The outcome was patients disease 
relapse. We recorded 105 events of CRC relapse among 425 stage II and III CRC patients. At 
univariate analysis, increasing values of CD68
+
 [HR=0.77 95%CI (0.64-0.93), P=0.007], 
CD3
+
 [HR=0.75 95%CI (0.60-0.94), P=0.01] and Foxp3
+ 
[HR=0.76 95%CI (0.63-0.90) 
P=0.002]
  
IRA were strongly associated with better patient outcome (Table 5). Other features 
associated with higher risk of disease recurrence were rectal site (P=0.03), TNM stage 
(P=0.001), grade of differentiation (P=0.02), and vascular invasion (P=0.001). Interestingly, 
we found an additive negative interaction between 5-FU adjuvant treatment and TNM stage 
[5-FU treated vs untreated in stage III patients p=0.051] in predicting patient’s disease 
relapse. Accordingly, among stage III CRC patients 5-FU adjuvant treatment had a tendency 
to be associated with a lower risk of disease relapse [HR=0.63, 95%CI (0.39-1.03), P=0.06]. 
In parallel, 5-FU adjuvant treatment was irrelevant in predicting prognosis among stage II 
CRC patients [HR=1.00, 95%CI (0.50-2.02), P=0.99]. This data is in accordance with data 
reported in the literature, since 5-FU adjuvant treatment is well known to be effective only 
among stage III CRC but not among stage II CRC. By systematically considering all the 
factors that may interact in determining patient prognosis, including the densities of immune 
cell populations, we found a significant interaction between the density of CD68
+ 
cells and 5-
FU treatment in patients with stage III CRC when predicting patient’s outcome(P=0.03). 
Differently, the interaction between categorical densities values of CD68
+
 TAM and 5-FU 
adjuvant treatment in predicting the risk of patients outcome was not significant in stage II 
CRC patients (P=0.50). These results suggest that 5-FU adjuvant treatment modifies the 
ability of CD68
+ 
TAM densities in predicting patient outcome in patients with stage III CRC. 
On the other hand when testing statistical interaction between categorical densities of CD3
+  
and Foxp3
+ 
cells and 5-FU adjuvant treatment
 in predicting the risk of patient’s outcome we 
couldn’t find any significant interaction in both stage II (P=0.88, P=0.48) and stage III 
(P=0.84, P=0.79) CRC patients respectively. Therefore, 5-FU chemotherapy did not modify 
the ability of adaptive immunity to predict the risk of patient’s outcome and vice versa. The 
interaction between the density of CD68 and 5-FU treatment in patients with stage III CRC 
was not the only significant one. In fact we also found that adaptive TILs, either CD3
+ 
or 
FoxP3
+
, interacted with TNM stage (P=0.02 and P=0.02 respectively) (Table 5). The detected 
roles of effect modifier exerted by 5-FU therapy with CD68
+
TAM in stage III patients and by 
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TNM staging with CD3
+ 
and FoxP3
+ 
TILs in predicting patients prognosis suggested that we 
should proceed with separate regression models of the prognostic value of TAM and TILs 
according to interacting variables.  
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Table 5.  Predictive factors for postsurgical relapse and their significant interactions in 
425 patients with stage II and III colorectal cancer. 
 
Tumour characteristics 
Relapse Univariate Analysis Interaction Model 
No Yes 
HR (95%CI) P P<0.05 
(n=320) (n=105) 
       
CD68-IRA 
0-4% 149 61 1.00 ref.  
X 5-FU therapy (α)  
in  stage III 
4%-8% 65 24 0.92 (0.58-1.48) 0.74 
8%-12% 37 10 0.66 (0.34-1.29) 0.22 
>12% 69 10 0.41 (0.21-0.82) 0.01 
       
CD3-IRA 
0-1% 77 37 1.00 ref.   
1-5% 140 44 0.72 (0.46-1.11) 0.14 
x TNM Stage (β) 5-10% 63 20 0.74 (0.43-1.28) 0.28 
>10% 69 10 0.26 (0.09-0.73) 0.01 
       
FoxP3-IRA 
0-0,2% 89 40 1.00 ref.   
0,2-0,4% 65 31 1.03 (0.64-1.65) 0.30 
x TNM Stage (γ) 0,4-0,7% 77 13 0.40 (0.21-0.75)   0.005 
>0,7% 80 18 0.51 (0.29-0.90) 0.02 
       
Patients Age (years, mean+SD)  1,01 (0,99-1,03) 0.12  
       
Gender 
Male 184 61 1.00 ref.   
Female 136 44 0.99 (0.67-1.92) 0.95  
       
Site 
Colon Dx 129 36 1.00 ref.  
 
Colon Sx 127 36 0.88 (0.55-1.42) 0.60 
Rectum 64 36 1.66 (1.04-2.64) 0.03  
       
MS-Status 
MSS 264 95 1.00 ref.  
 
MSI 56 10 0.66 ( 0.34-1.26) 0.21 
      
TNM Stage 
II 184 32 1.00 ref.  x (β)  
x (γ) III 136 73 2.62(1.73-4.00) <0.001 
<0.001 
       
Grade 
G1/G2 268 79 1.00 ref.   
G3 52 26 1.68 (1.08-2.61) 0.02  
       
Cell Type 
ADC 296 92 1.00 ref   
Variants 24 13 1.60 (0.90-2.86) 0.11  
       
Vascular  
Invasion 
No 258 69 1.00 ref  
 
Yes 62 36 1.97 (1.32-2.95)   0.001 
       
5-FU Adjuvant Therapy     
Stage II 
No 107 18 1.00 ref   
Yes 77 14 1.00 (0.50-2.00) 0.99  
Stage III 
No 36 26 3.66 (2.00-6.68) 
§ x (α) 
Yes 100 47 2.77 (1.31-3.91) 
       
 
§Expected H.R., 3.66, additive negative interaction; 5-FU chemotherapy in stage III CRC patients, yes vs no, H.R. 
0.62 (0.38-1.00), p=0.051 
α The interaction between CD68-IRA and 5-FU CHT in stage III (α) is statistically significant when CD68-IRA is entered as a 
categorical variable (α, P=0.03).  
β The interaction between CD3-IRA and TNM staging (β) is statistically significant when CD68-IRA is entered as a categorical 
variable (β, P=0.020).   
γ The interaction between Foxp3-IRA and TNM staging (γ) is statistically significant when CD68-IRA is entered as a categorical 
variable (γ, P=0.021).   
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In clinical practice, significant differences exist between patients who receive or not 
chemotherapy treatment, particularly with regard to age, co-morbidities, and provider/patient 
preferences. To address selection bias and to find whether CD68IRA% covariates with any 
demographic, clinical and histo-pathological characteristics owing to non-random treatment 
assignment we checked for clear group differences of CD68IRA% distribution by 5-FU 
chemotherapy treatment. Table 6 shows increasing values of CD68IRA% in stage III 
according to 5-FU adjuvant treatment on demographic clinical and histopathological 
characteristics. Increasing CD68
+
TAM densities did not covariate with any other variables 
assessed (table 6). 
 
Table 6.  CD68-Immunoreactive area  (IRA, % of microscopic field) at the  
Invasive Margin of  209 Stage III Colorectal Cancers according to adjuvant 
treatment.  
  Adjuvant treatment 
  No chemotherapy 5-FluoroUracyle 
CD68IRA%  Median Value P Median Value P 
      
Patient Age  
≤68 yrs 2.11 
 0.33 
3.99 
0.41 
>68 yrs 3.57 3.44 
      
Patient Gender 
Male  3.41 
  0.53 
4.01 
0.22 
Female 4.42 3.93 
      
Microsatellite Status 
MSS 3.47 
0.35 
3.97 
0.70 
MSI 3.22 3.26 
      
Tumor Site 
Colon Dx 3.15 
0.30 
3.25 
0.43 Colon Sx 3.45 3.08 
Rectum 4.28 6.02 
      
Tumor Grade 
G1/G2 4.12 
0.10 
3.98 
0.85 
G3 2.65 3.78 
      
Tumor Cell Type 
ADC 4.12 
0.05 
4.13 
0.16 
Variants 1.52 2.31 
      
Vascular Invasion 
No 3.42  
0.77 
3.87 
0.89 
Yes 4.39 3.95 
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4.4 Prognostic value of CD68
+
TAM at the tumour invasive front according to 5-FU 
adjuvant treatment and TNM stage  
We inspected the effect modification exerted by 5-FU adjuvant treatment and CD68
+ 
TAM 
densities in predicting the risk of patient’s relapse according to TNM tumour staging, by 
performing subgroup analysis. The predictive value of CD68
+ 
TAM in CRC patients who 
received or not 5-FU chemotherapy in stage II and III subgroups of CRC patients is shown in 
table 6. Among stage II CRC patients increasing values of CD68
+ 
TAMs densities were not 
associated with prognosis in both 5-FU adjuvant treated [n=147 HR=0,93; 95%CI (0,57-
1,52); P=0.77] and chemotherapy un-treated patients [n=62 HR=0,77 95% CI (0,50-1,19); 
P=0.24]. However, when considering stage III subgroup of CRC patients we found that  
increasing values of CD68
+ 
TAM densities were associated with a lower risk of disease 
progression only among CRC patients receiving 5-FU adjuvant treatment [n= HR=0,64; 
95%% CI (0,47-0,87) P=0.005], but not among patients that didn’t receive any adjuvant 
treatment [n= HR=1,07; 95% CI (0,74-1,54) P=0.71].  
 
Table 7. Prognostic value of CD68
+
TAMs densities in 425 stage II and III CRC 
according to TNM stage and 5-FU adjuvant therapy. 
 
 
 Tumour Stage 
 Stage II  Stage III 
 Relapse    Relapse   
CD68 IRA  No Yes HR (95%CI) P  No Yes HR (95%CI) P 
           
5-FU Therapy = No           
0-4%  49 12 1.00 Ref   20 13 1.00 Ref  
4-8%  17 2 0.55 (0.12-2.47) 0.44  9 7 1.09 (0.43-2.74) 0.84 
8-12%  16 1 0.28 (0.04-2.16) 0.22  3 2 0.76 (0.17-3.41) 0.72 
>12%  25 3 0.61 (0.17-2.16) 0.44  4 4 1.39 (0.45-4.30) 0.55 
           
5-FU Therapy = Yes           
0-4%  34 6 1.00 Ref   46 30 1.00 Ref  
4-8%  20 4 1.14 (0.32-4.05) 0.83  19 11 0.87 (0.44-1.75) 0.71 
8-12%  10 3 1.59 (0.39-6.43) 0.51  8 4 0.76 (0.27-2.17) 0.61 
>12%  13 1 0.46 (0.05-3.87) 0.47  27 2 0.14 (0.03-0.61) 0.008 
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Scatter plots of CD68
+
 TAM densities according to CRC disease recurrence and adjuvant 
therapy in stage III or in stage II are shown in figure 3 and 4, respectively. When considering 
stage III CRC patients, among 5-FU adjuvant treated cancers CD68IRA% was significantly 
lower (P=0.008) in patients with evidence of disease relapse (n=100; median=4,21%; second-
third quartile=1.81% – 12.25%) compared to patients with no evidence of tumour progression 
(n=47; median=2,37%; second-third quartile=0.41% – 5.82%) (Figure 3). Conversely, 
CD68IRA% was not different in stage III CRC patients who did not receive chemotherapy 
adjuvant treatment (P=0.89) with (n=36; median=3.47%; second-third quartile=2.26% – 
6.52%) or without (n=26; median=3.64%; second-third quartile=0.93% – 7.66%) evidence of 
disease progression (Figure 3).   
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Figure 3. Distribution of CD68
+
TAM densities at the tumour invasive front in Stage III 
CRC patients according to occurrence of disease progression and adjuvant 
chemotherapy treatment. 
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Among Stage II CRC patients CD68IRA% densities were not differing when comparing 
patients with or without evidence of tumour progression, in both 5-FU adjuvant treated 
(P=0.36) or untreated patients (P=0.74) (Figure 4).  
 
Figure 4. Distribution of CD68
+
TAM densities at the tumour invasive front in Stage II 
CRC patients according to occurrence of disease progression and adjuvant 
chemotherapy treatment. 
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Figure 5a shows Kaplan Meyer survival curves of stage III CRC patients sub-grouped by 
values above (“high”) or below (“low”) the median density of CD68+ TAMs. Patients who 
received 5-FU treatment and had a high density of CD68
+
 TAMs had a better outcome 
(P=0.02) (figure 5a). On the contrary, the prognosis of stage III CRC patients that didn’t 
receive any chemotherapy treatment was not affected  (P=0.75) by densities of CD68
+
 (figure 
5a).  
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Figure 5A. Kaplan-Meyer survival curves showing disease specific survival (DSS) for 
stage III CRC. The median value (4.12%) of CD68
+ 
TAMs in the overall population was 
used to define high CD68
+
TAMs. 
Figure 5B. Kaplan-Meyer survival curves showing disease specific survival (DSS) for 
stage III MSS CRC. The median value (4.12%) of CD68
+ 
TAMs in the overall 
population was used to define high CD68
+
TAMs. 
  
63 
 
4.5 Predictive value of CD68
+
TAM density in response to 5-FU treatment is enhanced in 
stage III chromosomal instable tumours. 
Ms-Status is an important determinant of CRC responsiveness to 5-FU adjuvant treatment, 
(i.e., predictive factor). For this reason, we tested whether the type of genetic instability might 
influence the ability of CD68
+ 
TAMs to predict the prognostic advantage of 5-FU adjuvant 
treatment in CRC patients. Of note, it is relevant to acknowledge that the low prevalence of 
MSI CRC patients translated in to only modest power to detect a statistically significant 
finding for an interaction effect with this variable. When MSI patients were removed from the 
model, among stage III CRC the interaction between  increasing values of CD68
+ 
TAMs 
densities and 5-FU adjuvant treatment in predicting disease progression increased its 
statistical power (P=0.01). For that reason, we suspect that the type of Ms-status might 
modify the ability of TAMs to predict chemotherapy efficacy. Considering only stage III MSS 
CRC, increasing values of CD68
+
TAM were associated with improved prognosis [n=130, 
HR=0.55; 95%CI (0.39-0.80); P=0.001] among patients that received 5-FU chemotherapy 
treatment. On the contrary, increasing values of CD68
+
TAM densities in stage III MSI CRC 
were irrelevant to predict patient’s prognosis [n=54 HR=1.05; 95%CI (0.73-1.52); P=0.77] 
among patients that didn’t receive chemotherapy adjuvant treatment. Figure 5b shows Kaplan 
Meyer cancer related survival curves of stage III MSS CRC grouped by the density of CD68
+
 
TAMs. In the subset of stage III CRC patients, when we removed MSI patients from the 
analysis, an higher (>4,12%) density of CD68
+
 TAM was associated with better cancer related 
survival (P=0.006) among patients that received 5-FU adjuvant chemotherapy treatment 
(Figure 5b). Conversely, the cancer related survival of stage III CRC patients who didn’t 
receive chemotherapy did not change (P=0.84) according to CD68
+
 TAM density (>median) 
(Figure 5b).  
  
64 
 
In table 8 are shown the predictive abilities of CD68
+ 
TAMs densities in stage III CRC 
patients with or without microsatellite instability stratified by 5-FU adjuvant treatment. 
Among stage III MSS CRC a higher density (>median, 4.12%) of CD68
+
 TAMs was 
associated with a lower risk of disease progression only among patients that received 5-FU 
adjuvant treatment  [HR=0.43, 95%CI (0.22-0.81), P=0.01] but not among patients that didn’t 
received any chemotherapy treatment [HR=1.10, 95%CI (0.49-2.46), P=0.80] (Table 8). 
Conversely, among stage III MSI CRC the density of CD68
+
 TAMs was not associated with 
patient’s outcome, in both 5-FU receiving or not CRC patients (Table 8). Importantly, among 
stage III MSS CRC patients with higher density of CD68
+ 
TAMs at the tumour invasive front, 
5-FU adjuvant treatment was associated with a lower risk of disease progression [HR=0.34, 
95%CI (0.16-0.75), P<0.001] (Table 8). Conversely, among stage III MSS CRC patients with 
a lower (<median) density of CD68
+ 
TAMs the risk of disease relapse was not affected 
[HR=0.89, 95%CI (0.45-1.74), P=0.73)] by 5-FU adjuvant treatment (Table 8). Therefore, our 
data evidence that in stage III CRC MSS patients, 5-FU chemotherapy treatment seems to be 
effective only when the primary tumour retains a relevant number of macrophages at the 
tumour invasive front. 
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Table 8. Likelihood of disease relapse in stage 209 III CRC, by postsurgical adjuvant therapy and TAM density in the 
primary tumour. 
 
 
5-FU Chemotherapy 
No Yes  Yes vs No  
Relapse HR (95%CI) P  Relapse HR (95%CI) P  HR (95%CI)* P 
 No Yes 
   
No Yes 
   
  
Stage III CRC 143 44 177 61   
             
MSS             
TAM 
Low 17 12 
1.10 (0.49-2.46) 0.80  
38 29 
0.43 (0.22-0.81) 0.01  
0.89 (0.45-1.74) 0.73 
High 13 12 49 14 0.34 (0.16-0.75) <0.01 
MSI             
TAM 
Low 3 1 
1.15 (0.07-18.59) 0.91  
9 1 
5.43 (0.55-52.91) 0.14  
0.42 (0.02-6.74) 0.54 
High 3 1 4 3 1.63 (0.16-15.87) 0.67 
             
 
*Risk of relapse with respect to 5-FU treatment within each subgroup 
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4.6 Prognostic value of CD3
+
 and Foxp3
+
Tils densities at the tumour invasive front 
according to TNM stage of disease 
Like CD68
+
 TAMs, we tested the effect modification of TNM staging by separately assessing 
the prognostic abilities of CD3
+
 and Foxp3
+ 
TILs in stage II and III CRC patients. 
Accordingly, the prognostic value of CD3
+
 and Foxp3
+ 
TILs in stage II and  stage III CRC 
patients is shown in table 9. Among stage II CRC patients, we found that a lower risk of 
disease progression was associated with  increasing values of CD3
+
 TILs [HR=0,49; 95% CI 
(0,31-0,77); P=0.002] and Foxp3
+ 
TILs densities [HR=0.50; 95% CI (0,34 - 0,74); P<0.001]. 
Conversely, among stage III CRC patients increasing values of CD3
+
 TILs [n= HR=0.94; 
95% CI (0.73-1.22); P=0.64] and Foxp3
+ 
TILs [n= HR=0.85; 95% CI (0,69 - 1,04); P=0.10] 
were irrelevant in predicting patient prognosis.  
 
Table 9. Prognostic value of CD3
+
TILs and FoxP3
+
Tils densities as a predictor of 
disease relapse according to TNM stage. 
 
 
 Tumour Stage 
 Stage II  Stage III 
 Relapse    Relapse   
  No Yes HR (95%CI) P  No Yes HR (95%CI) P 
           
CD3 IRA           
0-1%  37 16 1.00 Ref   40 21 1.00 Ref  
1-5%  83 12 0.40 (0.12-2.47) 0.02  57 32 1.06 (0.61-1.85) 0.81 
5-10%  38 2 0.15 (0.04-0.66) 0.01  25 18 1.35 (0.72-2.55) 0.34 
>10%  26 2 0.22 (0.05-1.00) 0.05  14 2 0.32 (0.07-1.40) 0.13 
           
FoxP3 IRA           
0-0,2%  52 18 1.00 Ref   37 22 1.00 Ref  
0,2-0,4%  40 10 0.72 (0.33-1.56) 0.40  25 21 1.35 (0.74-2.45) 0.33 
0,4-0,7%  44 2 0.15 (0.03-0.65) 0.01  33 11 0.57 (0.28-1.18) 0.13 
>0,7%  43 2 0.14 (0.03-0.63) 0.009  37 16 0.72 (0.38-1.37) 0.32 
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Scatter plots of individual densities of CD3
+
 and Foxp3
+ 
TILs are shown in figure 6 and 7. In 
the subgroup of stage II CRC patients CD3IRA% (P<0.001) and Foxp3IRA% (P<0.001) were 
significantly lower in patients with evidence of disease relapse (CD3IRA%: n=32, 
median=1.09, second-third quartile=0.38-2.46; Foxp3IRA%: n=32, median=0.12, second-
third quartile=0.00-0.28) compared to patients with no evidence of disease relapse 
(CD3IRA%: n=184, median=2.88, second-third quartile=1.23-6.41; Foxp3IRA%: n=179, 
median=0.39, second-third quartile=0.17-0.69). Conversely, in stage III CD3IRA% (P=0.60) 
and Foxp3IRA% (P=0.18) did not differ in CRC patients with (CD3IRA% : n=70; 
median=2.32; second-third quartile=0.78-5.59; n=70; Foxp3IRA%: median=0.29; second-
third quartile=0.12-0.66) or without (CD3IRA%: n=136; median=2.23; second-third 
quartile=0.89-5.59; Foxp3IRA%: n=132; median=0.42; second-third quartile=0.17-0.79) 
evidence of disease progression.  
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Figure 6. Distribution of CD3
+ 
Tils densities at the tumour invasive front in stage II and 
III CRC according to occurrence of disease progression. 
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Figure 7. Distribution of FoxP3
+ 
Tils densities at the tumour invasive front in stage II 
and III CRC according to occurrence of disease progression. 
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Figure 8 shows Kaplan Meyer prognostic curves of CRC patients studied sub-grouped by 
TNM tumour stage and CD3
+
 and FoxP3
+
TILs densities. Among patients with stage II CRC, 
those with a high density of CD3
+
 and FoxP3
+
 cells (>1.86%, >0.23% respectively) had a 
lower risk of tumour progression (P<0.001, P<0.001 respectively) compared to those with a 
lower density of CD3
+
 and FoxP3
+
 cells, while the prognosis of stage III CRC patients was 
not affected by the density of CD3
+
 and FoxP3
+
 cells (P=0.95, P=0.21 respectively) (figure 8).  
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Figure 8. Kaplan-Meyer outcome curves showing disease free survival (DFS). The cut-
off values generated from CART analysis (1.86% and 0.23%) were used to define high 
CD3
+
 and FoxP3
+
TILs respectively. 
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In figure 9 and 10 are shown the distribution of CD3
+
 and FoxP3
+
TILs according to the extent 
of lymph-node metastasis. Patients with ≤ 4 metastatic pericolic (or perirectal) lymph-nodes 
have N1, and patients with > 4 have N2 CRC. Of patients with no evidence of disease 
progression (n=320), the density of CD3
+
 cells was decreasing (P=0.01) along with the 
severity of lymph-nodal tumour involvement. Conversely, among patients who experienced 
tumour relapse (n=105) the density of CD3
+
 cells was increasing (P=0.04) along with extent 
of lymph-nodal tumour metastasis. Thus, among CRC patients that experienced relapse only 
those without any evidence of lymph-node metastasis had a lower density of CD3
+
 TILs 
(P<0.001) compared to those that didn’t experience relapse. (Figure 9)  
 
Figure 9. Distributions of CD3
+
TILs according to the extent of lymph-nodes metastasis 
and patient’s disease relapse. 
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Taking in consideration Foxp3
+
 cells, in CRC patients with no evidence of disease 
progression (n=311), the density Foxp3
+
 TILs did not change (P=0.34) according to the extent 
of lymph-nodal involvement. Conversely, among cancer patients that experienced tumour 
relapse (n=102) the density of Foxp3
+
 TILs increased (P=0.04) along with the extent of 
lymph-node tumour metastasis. (Figure 10) . 
 
 
Figure 10. Distributions of FoxP3
+
TILs according to the extent of lymph-nodes 
metastasis and patient’s disease relapse. 
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Chapter 5. CD68
+ 
TAM densities in metastatic lymph-nodes 
5.1 Density of CD68
+
TAM in the tumour margin of metastatic lymph-nodes and its 
correlation with clinicopathological features at the time of surgery. 
The ability of CD68
+
TAM in CRC primary tumor to predict response to 5-FU was detected 
only in stage III CRC patients. We investigated CD68
+ 
TAM density at the tumor margin in 
metastatic lymph-nodes from stage III CRC patients. In the entire population of stage III CRC 
patients the densities of CD68
+
TAM M-LN we studied ranged from 0% to 13.52 %. The 
median value of the distribution of CD68
+
TAM M-LN densities was 1.77% and the first and 
the third quartile were 0.57% and 4.56% respectively. The distribution of CD68
+ 
TAM-IRA 
M-LN according to demographics, clinical and histopathologic characteristics in the 
population of CRC patients recruited in this study is shown in appendix table 2. CD68IRA% 
M-LN did not correlate with any of the variables assessed in this study.  
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5.2 Density of CD68
+
TAM in the tumour margin of metastatic lymph-nodes and its 
correlation with patient’s outcome  
To validate the predictive ability of CD68
+ 
TAM density in the primary tumor we investigated 
whether CD68
+ 
TAM density in M-LN also correlates with the prognosis of CRC patients. As 
shown in table 10, we performed univariate and multivariate Cox regression analysis of the 
densities of CD68
+ 
TAM M-LN according to the outcome of CRC patients. We recorded 49 
events of CRC disease relapse among 135 stage III CRC patients. At univariate analysis 
increasing densities of CD68
+
 TAM M-LN [HR=0.65 95%CI (0.49-0.86), P=0.002] densities 
were strongly associated with better patient outcome. Other features associated with higher 
risk of disease recurrence were rectum site (P=0.03) and vascular invasion (P=0.003). To 
confirm whether 5-FU adjuvant treatment modifies the abilities of CD68
+
TAM densities in 
metastatic lymph-nodes to predict CRC patients prognosis, we performed interaction analysis. 
Accordingly, by entering into a logistic regression model the categorical density values of 
CD68
+
 TAM M-LN, 5-FU adjuvant treatment and a product term consisting of the 
multiplication of the above variables we found a statistical interaction when predicting the 
risk of patient’s outcome (P=0.03). This result indicates that 5-FU adjuvant treatment modify 
the ability of CD68
+ 
TAM densities in metastatic lymph-nodes in predicting the risk of 
patient’s outcome, thus confirming results obtained in the primary tumour. (Table 10). 
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Table 10.  Predictive factors for postsurgical relapse and their significant interactions 
in 135 CRC patients of stage III colorectal cancer. 
 
 
 
Relapse Univariate Analysis Interaction Model 
No Yes 
HR (95%CI) P P<0.05 
(n=86) (n=49) 
       
CD68-IRA M-LN      
0-1% 24 25   
x 5-FU therapy (α) 
 1-3% 23 14 0.69 (0.35 – 1.32) 0.26 
 3-5% 15 4 0.32 (0.11 – 0.92) 0.03 
 >5% 24 6 0.30 (0.12 – 0.75)   0.009 
       
Age (years, mean+SD)  1,01 (0,99-1,03) 0.12  
       
Gender       
Male 54 29 1.00 ref.   
Female 32 20 1.16 (0.65-2.06) 0.59  
       
Tumor Site      
Colon 69 30 1.00 ref.   
Rectum 17 19 1.85 (1.04-3.30) 0.03  
       
Tumor MS Status     
MSS 72 47 1.00 ref.   
MSI 14 2 0.31 ( 0.07-1.27) 0.10  
      
Tumor Grade       
G1/G2 62 31 1.00 ref.   
G3 24 18 1.43 (0.80-2.57) 0.21  
       
Tumor Cell Type     
ADC 74 41 1.00 ref   
Variants 12 8 1.13 (0.53-2.42) 0.74  
       
Tumor Vascular Invasion      
No 65 25 1.00 ref   
Yes 21 24 2.28 (1.30-4.01) 0.003  
       
5-FU Adjuvant Therapy     
No 20 11 1.00 ref  
x (α) 
Yes 66 38 0.79 (0.40-1.56) 0.50 
       
 
°   Age entered as a continuous variable   
The interaction between CD68-IRA M-LN and 5-FU CHT is statistically significant when CD68-IRA M-LN is 
entered as a categorical (α, P=0.03) or a continuous variable (α, P=0.009).   
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5.3 Prognostic ability of CD68
+
TAM  in the tumour margin of metastatic lymph-nodes 
according to 5-FU adjuvant treatment.  
Considering the significantly interacting variables only, we tested the effect modification of 5-
FU adjuvant treatment on the ability of densities of CD68
+ 
TAM in metastatic lymph-nodes in 
predicting the risk of patient’s relapse by performing subgroup analysis. The predictive value 
of CD68
+ 
TAM in CRC patients that received 5-FU chemotherapy or not is shown in table 11. 
Among 5-FU adjuvant treated CRC patients  increasing values of CD68
+ 
TAMs densities in 
the metastatic lymph-nodes were associated with better prognosis [n=104; HR=0.54; 95%CI 
(0.39-0.76); P<0.001]. Conversely among chemotherapy un-treated CRC patients  increasing 
values of CD68
+ 
TAMs densities were not associated with prognosis [n=31; HR=1.13; 95% 
CI (0-67-1.90); P=0.64]. (Table 11) 
 
Table 11. CD68
+
TAM density at the tumor margin in metastatic lymph-nodes as a predictor 
of disease relapse according to 5-FU adjuvant therapy. 
 
 
 
 Adjuvant Treatment* 
 5-FU Therapy  No chemotherapy 
 Relapse    Relapse   
  No Yes HR (95%CI) P  No Yes HR (95%CI) P 
           
CD68-IRA M-LN*           
0-1%  16 20 1.00 ref   8 5 1.00 ref  
 1-3%  17 13 0.75 (0.37 – 1.51)  0.42  6  1 0.34 (0.04 – 2.96) 0.33 
 3-5%  12 2 0.18 (0.04 – 0.80) 0.02  3  2 0.89 (0.17 – 4.62) 0.89 
 >5%  21 3 0.16 (0.04 – 0.56) 0.004  3 3 1.47 (0.34 – 6.32) 0.60 
           
 
*The interaction between CD68-IRA M-LN and 5-FU CHT is statistically significant when CD68-IRA M-LN is 
entered as a categorical (α, P=0.03) or a continuous variable (α, P=0.009). 
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Figure 12 shows scatter plots of individual CD68
+
 TAM densities in metastatic lymph-nodes 
according to CRC disease recurrence. Among 5-FU adjuvant treated patients CD68IRA% M-
LN was significantly lower (P<0.001) in patients with evidence of disease relapse (n=38; 
median=2.92%; second-third quartile=1.04% – 5.74%) compared to patients with no evidence 
of tumour progression (n=66; median=2,37%; second-third quartile=0.41% – 5.82%). 
Conversely, CD68IRA% was not differing in patients that did not receive chemotherapy 
adjuvant treatment (P=0.96) with (n=11; median=2.03%; second-third quartile=0.11% – 
5.72%) or without (n=20; median=1.76%; second-third quartile=0.33% – 3.32%) evidence of 
disease progression (Figure 12).  
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Figure 12. Distributions of CD68
+
TAM densities at the tumour margin of metastatic 
lymph-nodes according to occurrence of disease progression and chemotherapy 
adjuvant treatment.  
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Figure 13 shows Kaplan Meyer survival curves sub-grouped by (>median) CD68
+
 TAMs 
densities in metastatic lymph-nodes and 5-FU adjuvant treatment. Among patients that 
received 5-FU adjuvant treatment those with a high (>median) density of CD68
+
 TAMs M-
LN had a better DSS (P<0.001) than those with a low density (figure 13). Again, the DSS of 
CRC patients who didn’t receive chemotherapy was not affected (P=0.86) by densities of 
CD68
+
 TAMs M-LN (figure 13). Therefore, the predictive effect of CD68 
+
TAM on the 
effectiveness of 5-FU chemotherapy treatment was confirmed in metastatic lymph-nodes 
indicating that CD68
+
TAM effect modification on chemotherapy is maintained in tissues 
other than the intestine.   
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Figure 13. Kaplan-Meyer survival curves according to chemotherapy adjuvant 
treatment. CD68
+
TAM median density in metastatic lymph-nodes was used to define 
high CD68
+
TAM. 
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Supplementary appendix 
 
Appendix Table 1: Patient demographics, tumour 
pathological features and microsatellite status of 425 
stage II and III colorectal cancers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
  
N (%) 
   
Patient Age   
≤69 yrs 228 (53.6%)  
>69 yrs 197 (46.4%) 
   
Patient Gender 
Male  245 (57.7%) 
Female 180 (42.4%) 
   
Tumor Site 
Colon 321 (75.5%)  
Rectum 104 (24.5%) 
   
Microsatellite status 
MSS 359 (84.5%) 
MSI 66 (15.5%) 
   
Tumor Stage 
II 216 (50.8%) 
III 209 (49.2%) 
   
Tumor Grade 
G1/G2 347 (81.6%) 
G3 78 (18.4%) 
   
Tumor Cell Type 
ADC 388 (91.3%) 
Variants 37   (8.7%) 
   
Vascular Invasion 
No 327 (76.9%) 
Yes 98 (23.1%) 
   
5-FU Adjuvant Therapy    
Stage II 
No 125 (57.9%) 
Yes 91 (42.1%) 
 Stage III 
No 62 (29.7%) 
Yes 147 (70.3%) 
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Appendix Table 2. CD68-Immunoreactive area  (IRA, % of microscopic 
field) at the  tumour margin of  metastatic lymph-nodes in 135 Stage III 
Colorectal Cancers.  
 
 
     
  Median 
Value 
2
nd
-3
rd
 quartile 
Univariate* 
 P 
     
Patient Age °  
≤69 yrs 2.02 0.57 -   4.66  
>69 yrs 1.39 0.38 -   4.67 0.42 
     
Patient Gender 
Male  2.31 0.58 -   4.90  
Female 1.23 0.48 -   3.75 0.19 
     
Microsatellite Status 
MSS 1.44     0.55 -  4.49  
MSI 2.55   0.90 - 6.26 0.25 
     
Tumor Site 
Colon 1.89 0.70 -   4.69  
Rectum 1.39   0.35 -   3.18 0.46 
     
Tumor Grade 
G1/G2 2.09 0.74 -   4.63  
G3 1.10 0.31 -   4.49 0.33 
     
Tumor Cell Type 
ADC 2.03 0.58 -   4.63  
Variants 1.37 0.18 -   4.51 0.42 
     
Vascular Invasion 
No 2.11    0.74 - 4.49  
Yes 1.17 0.44 -   4.90 0.55 
     
5-FU Adjuvant Therapy 
No 2.03 0.19 –   4.40  
Yes 1.73 0.72 –   4.66 0.50 
     
 
 *   Linear Regression Analysis.  “CD68-IRA%“ was entered as a dependent, continuous 
variable.  
  
 °   Age entered as a continuous variable   
CD68-IRA% values of in patients  whose age was below or above the median age of the 
entire series, are shown only for a descriptive purpose.  
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Appendix Figure 1.   
Receiver Operating Characteristic (ROC) analysis of CD68
+
 IRA% TAMs as a 
predictor of prognosis in patients with stage III CRC 5-FU adjuvant treated. Area under 
the curve 0.63. At a cut-off value of 7.59 %, sensitivity was 0.87, specificity 0.36. 
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Appendix Figure 2.   
Receiver Operating Characteristic (ROC) analysis of CD68
+
 IRA% TAMs as a 
predictor of prognosis in patients with stage III MSS CRC 5-FU adjuvant treated. Area 
under the curve 0.67. At a cut-off value of 7.59 %, sensitivity was 0.90, specificity 0.37. 
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Appendix Figure 3   
Receiver Operating Characteristic (ROC) analysis of CD68
+
 IRA% TAMs in metastatic 
lymph-nodes as a predictor of prognosis in patients with stage III MSS CRC 5-FU 
adjuvant treated. Area under the curve 0.67. At a cut-off value of 0.81%, sensitivity was 
0.82, specificity 0.51. 
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Appendix Figure 4.   
Receiver Operating Characteristic (ROC) analysis of CD3
+
 IRA% TILs as a predictor 
of prognosis in patients with stage II CRC. Area under the curve 0.69. At a cut-off value 
of 1.85 %, sensitivity was 0.75, specificity 0.61. 
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Appendix Figure 5.   
Receiver Operating Characteristic (ROC) analysis of FOXP3
+
 IRA% TILs as a 
predictor of prognosis in patients with stage II CRC. Area under the curve 0.72. At a 
cut-off value of 0.23 %, sensitivity was 0.75, specificity 0.66. 
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Appendix Figures 6 to 8. Examples of increasing amounts of immunoreactive surfaces 
covered by CD68IRA%,CDIRA% and FOXP3IRA% cells, detected at the invasive front 
of CRC by a computer-aided image analysis system. (Objective magnification 10x) 
  
Appendix Figure 6 . Rappresentative images of CD68IRA% 
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Appendix Figure 7. Rappresentative images of CD3IRA% 
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Appendix Figure 8. Rappresentative images of FOXP3%IRA 
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Appendix Figure 9. Rapresentative image of an immunoreactive surface covered by 
CD68
+
 cells in a whole lymph-node partially metastatic. 
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Discussion 
This study greatly expands our original observation that the prognostic value of immune cells 
infiltrating CRC changes with disease progression. We first reported that CD3
+
 TILs and 
tumour stage interact in determining patients prognosis 
92
. In the present study we detected 
two other effect modifications associated with CRC infiltrating cells. The first one occurs 
between CD68
+
TAM and 5-FU adjuvant chemotherapy in patients with stage III CRC in 
determining the outcome after adjuvant treatment. The second interaction occurred between 
FOXP3
+ 
TAM and TNM stage and resembles that originally reported for CD3
+
 TILs.  
The most innovative finding of the present study is represented by the identification of TAM 
as a novel predictive marker of response to 5-FU adjuvant treatment in stage III CRC. In our 
dataset TAMs modifies the effect of 5-FU adjuvant treatment in exerting antitumor activity. 
Accordingly, we demonstrated that 5-FU adjuvant treatment in stage III was most efficient in 
exerting antitumor activity in tumours with high levels of TAM, while in patients with a low 
density of TAM chemotherapy was not effective in improving patient outcome. These data 
were obtained in a patient dataset including a “control arm” of chemotherapy untreated 
patients. Results also exclude that adaptive immunity, represented by CD3
+ 
and FOXP3
+ 
TILs 
might retain any ability to modify 5-FU adjuvant treatment effectiveness in predicting patient 
prognosis (in both stage II and III patients). To date, most studies relating adaptive immune 
cell densities and CRC prognosis didn’t reveal that any immune effectors was modified by 5-
FU adjuvant treatment in their predictive value. Only two studies from Morris and Halama 
reported association between chemotherapy response and levels of adaptive immune cells in 
patients prognosis 
138,139. However, it is important to underline that the first study didn’t report 
any effect modification of the predictive abilities of adaptive immune cells by statistical 
interaction with 5-FU, while the latter lacked of a control group of untreated CRC patients. 
Differently, very few studies assessed TAM prognostic abilities in CRC, and no one took 
advantage of computer assisted image analysis to measure immune cell density. This 
technology has the advantage to provide continuous values for immune cell quantity. 
Accordingly, data are more informative, detailed and statistically relevant in representing 
immune cells densities and their relevance on prognosis. A weakness of our retrospective 
study is represented by the non-random assignment of 5-FU adjuvant treatment. In clinical 
practice, significant differences exist between patients who receive or not adjuvant treatment, 
particularly with regard to age. However, to address selection bias owing to non-random 
treatment assignment we excluded that TAM density may covariate with any demographic 
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and clinico-pathological variable by performing separate analysis of TAM distributions in 
patients who received 5-FU adjuvant treatment and those who did not. Since TAM 
distribution was balanced across different groups of patients, we exclude any need for 
covariates adjustments in our prognostic models.  
Different clinical studies showed that MSI is a negative predictive marker of response to 5-FU 
in CRC by providing evidence that patients with MSI tumours did not received a survival 
benefit 
128-131,135
. This concept was demonstrated also in experimental studies in vitro and in 
vivo 
125-127
. Our data shows that TAM enhanced their predictive ability in MSS tumours, thus 
providing partial  biological explanation for the unresponsiveness of cancers with MSI 
molecular features to 5-FU treatment. However, it is relevant to notice that the low prevalence 
of MSI patients translated into only modest power to detect a statistically significant finding 
for an interaction effect with this variable. Therefore, it would be relevant to address this issue 
in larger dataset of patients. 
To assess whether the protective effect of high TAM density in stage III patients treated with 
5-FU adjuvant therapy is not restricted to the primary tumour, we studied TAM density in 
metastatic lymph-nodes of stage III CRC patients. The predictive effect of TAM density in 
metastatic lymph-nodes was clear-cut, results in metastatic lymph-nodes validate TAM 
predictive effect that we observed in the primary tumour, thus confirming that the presence of 
a high density of TAM is coupled with clinical response of stage III CRC patients to 5-FU 
adjuvant therapy. These data also demonstrate that such effect modification is mirrored in a 
non-colonic tissue microenvironment, different by the one where the tumour arise. Therefore, 
we speculate that TAM antitumour effect in conjunction with 5-FU might be exerted also on 
metastatic tumour clones far from the primary site, not clinically detectable. Moreover, the 
substantial correlation between TAM levels in the primary tumour and those in the lymph-
nodes metastasis suggest that pathways involved in TAM recruitment at the tumour border 
operate in metastatic lymph-nodes.  
Cancer immunoediting theory fits to dynamics of clinical progression of early stages of CRC 
not associated with CAC. In this case surgery removes macroscopically detectable colon 
cancer burden by physical excision while adjuvant chemotherapy is administered by assuming 
that it will kill circulating tumour cells and micrometastasis that spread out in the body. Such 
cells are not detectable by conventional diagnostic methods and are likely in a dormant state, 
and later they may give rise to metachronous metastasis, the main cause of death in colorectal 
cancer. Immune system might play a role in this process by keeping not detectable 
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micrometastasis in an equilibrium phase, while the evolution of such tumour cells might give 
them the chance to escape immune system recognition and cause recurrence. Adjuvant 
chemotherapy gives a clear survival advantage to CRC patients, though its role on immune 
system micrometastasis recognition and clearance is still unknown. Robust epidemiological 
evidence suggests that 5-FU adjuvant treatment does not exert any beneficial effect on 
patient’s prognosis among stage II patients. Moreover, in our data 5-FU adjuvant treatment in 
stage II CRC was not effective in improving patient’s relapse, regardless of CD68+TAM 
density. Chemotherapy seems to have beneficial effects only at a stage of disease when 
tumour clones have spread to metastatic lymph-nodes and perhaps to the body, although not 
clinically detectable. Despite clinical evidence, the biological and molecular basis of the 
discrepancies of chemotherapy benefit along CRC progression remain unknown. The current 
lack of valid experimental models that mirror different stages of CRC patients progression fits 
at least in part with this lack of knowledge. However, it is tempting to speculate that 
chemotherapy might overcome immune-escape mechanisms by causing alteration in antigenic 
properties of tumour clones that might modify tumour cell immunogenicity and recognition 
by the innate immune system. In this scenario, our data clinically suggest that 5-FU 
chemotherapy and TAM might play a synergic role in recognition and elimination of tumour 
clones by immune system with 5-FU being an efficient activator of  antitumour immune 
responses.  
Accumulating evidence suggests that certain chemotherapeutic agents can confer to tumour 
cells immunogenic abilities 
110-112
. The National Cancer Institute strategies to select 
conventional antineoplastic agents with the best ability to kill cancer cells of most solid 
tumours have been developed to date on murine immunodeficient host based on drugs ability 
to directly interact with cancer cells and thus to inhibit their growth or induce cell death 
102, 
103
. However, this strategy completely neglect that the host immune system might have any 
effect or interaction on tumour eradication in the context of chemotherapy. Accordingly, not 
much clinical data in CRC support the predictive value of immune effectors in contributing to 
chemotherapy effects. Since tumour infiltrating immune effectors might contribute to the 
efficacy of CHT, it is emerging that an immunological link might exists between CHT-driven 
antitumor activity and patients’ prognosis 110-112. Macrophages are the most prevalent antigen-
presenting cells in tumours and in certain cases may account for about 50% of the tumour 
mass 
70
. Both DCs and macrophages have the ability to pick up tumour antigens for cross-
presentation on MHC class I molecules 
115
. In this context it is important to consider that a 
recent paper from De Visser challenged the idea that adaptive system may increase 
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chemotherapy-mediated tumour cell death proposed by Zittvogel and colleagues 
117
. 
Understanding why the adaptive immune system does not contribute to chemoresponsiveness 
may yield to new strategies or new cellular mediators able to enhance chemotherapy-driven 
antitumor activity. In this setting our study suggest TAM as a new player in chemotherapy 
driven tumour cell death, thus in vivo functional studies in reliable immunocompetent 
experimental models of CRC are required to understand TAM behaviour on tumour cells in 
the context of 5-FU chemotherapy.  
We have no experimental explanation for the detected predictive role of TAM. First, it should 
be underlined that negative predictive role of TAM has been reported in patients with 
Hodgkin lymphoma (HL) 
144
. In that setting it has been found that patients with a higher 
number of CD68
+
 TAM were proposed as a new marker for prediction of worst outcome after 
primary and secondary treatment. The effect modification of TAM and chemotherapy in HL 
is only speculative due to the lack of a control arm, comprising untreated patients. However, 
the so called natural history scenario of disease is no longer seen in the 21
st
 century. The 
situation is different in our dataset, comprising both treated and untreated patients and 
encompassing different disease stages. However, TAM density was determined at diagnosis, 
before the administration of any treatment. This clearly demonstrates that TAM density at 
diagnosis is indeed a modifier of response to chemotherapy, later on. It is important to 
consider that HL is a lymphoid cancer with haematological origin and thus with a different 
lineage compared to epithelial cancers such as CRC and receiving different chemotherapy 
treatments. The opposite TAM predictive effect can be due to the different disease and 
affected cell of origin or the employed drugs, or both. Recently, in an experimental model of 
metastatic pancreatic ductal adenocarcinoma (PDAC) has been shown that treatment with 
CD40 ligand caused tumour regression
145
. In this process TAM were found to be functionally 
necessary to mediate antitumour activity, while TILs were irrelevant. This exciting and 
surprising result is the first experimental evidence that TAM directly exert antitumour activity 
in cancer, even though only when re-educated by CD40 ligand. In this experimental model of 
PDAC, CD3
+
 T cells (which are the major contributors of CD40 ligand) were not observed to 
infiltrate tumours before and after treatment with CD40 as well as in PDAC patients with 
metastatic disease
145
. In this scenario the variability and the complexity of cancer 
microenvironment among different patients with the same tumour type suggest that the 
clinical exploitation of TAM require careful and further analysis. In order to understand the 
behaviour of this player of inflammation in functional models is crucial to take in account the 
different tumour types and the different settings of cancer disease progression. 
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There’s general consensus supporting the fact that CRC development is positively influenced 
by the host immune system (Reviewed in Roxburgh
86
 and Table 2.4.2.1). Adaptive immune 
markers are powerful prognostic markers able to identify CRC patients that are more likely to 
experience cancer recurrence and thus might facilitate clinical decision-making regarding the 
necessity for adjuvant systemic therapy. However, this study is the first evidence of TAMs as 
the most promising candidate as predictive biomarkers in stage III CRC and that adaptive 
immune cells levels seems not to modify the effectiveness of 5-FU adjuvant therapy.  
We confirmed in a larger dataset of CRC patients data that our group have previously 
published 
92
. In this study high levels of CD3
+
TILs identified stage II CRC patients with a 
very low risk of cancer progression. However, in stage III the recruitment of even very dense 
TILs is irrelevant to the prognosis of patients. Despite conflicting data in the literature, we 
suggest that TNM staging still represent the best single prognostic indicator which justify its 
clinical use. As long as the tumour doesn’t gain the ability to invade and macroscopically 
colonize mesenteric lymph-nodes the extent of T-lymphocytes recruitment in the tumour 
seems to play an inhibitory effect on tumour progression, for that reason increasing 
recruitment of TILs in stage II CRC is expected to exert antitumour activity. In this view we 
speculate that in stage II tumour immunoescape mechanisms seem to act along TILs 
recruitment, as CRC that doesn’t have proper potential to recruit TILs will experience relapse 
and progression of disease. On the other hand, as long as tumours acquire the ability to spread 
and colonize mesenteric lymph-nodes TILs doesn’t seem to retain any antitumour activity, 
because tumour progression and relapse of disease will occur regardless of the extent of TILs 
recruitment. Therefore, in this setting lymph-nodal tumour metastasis might represent an 
alternative way for tumour  immunoescape. Taken together, our data provide the first 
evidence that tumour immunoescape seems to act through two different strategies. The first 
feature resides in the ability of tumours to recruit TILs which is likely dependent on the 
antigenic potential of stage II tumours. The second strategy lies in the potential of T-
lymphocytes recruited at the tumour site to exert antitumour activity, which is likely a feature 
of their cytotoxic activity. Therefore, the antitumour activity of TILs seems to be dependent 
on the presence of metastasis in the lymph-nodes regardless of their extent of recruitment at 
the tumour site. This last hypothesis was supported by a study from Koch wherein authors 
found that the proportion of activated TILs decreased significantly in higher tumour stage 
(from stage II through stage III to stage IV), giving functional assessment of increasing 
immune evasion along with more advanced clinical histopathologically staging 
62
. In a study 
from Atreya authors further supported this concept by showing that the proportion of 
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activated CD8+ TILs is not the only relevant feature in mediating CTL antitumor activity, as 
their cytolytic abilities is determinant to mediate an effective antitumor activity 
63
. Authors 
demonstrated that eomesodermin, a T-box transcription factor involved in controlling the 
cytotoxic activity of CD8+ CTLs, is inversely correlated with the presence of lymph node 
metastasis at diagnosis in CRC patients 
63
.These data together provide molecular basis for a 
role of lymph-nodes metastasis in this phenomena. In this new scenario, the development of 
immuno-therapies strategies aimed to enhance antitumour activities of TILs should take 
account of such the immunoescape mechanisms along the state of CRC progression at 
diagnosis.  
Another important result of our study regards a subpopulation of T-lymphocytes expressing 
the transcriptional factor FOXP3 which we found to retain positive prognostic ability, as 
demonstrated by other studies. However, this is the first study demonstrating that, alongside 
CD3
+
TILs, the recruitment of FOXP3
+
TILs exert antitumour activity only among CRC 
without lymph-nodal metastasis. These data further corroborate the idea that in stage II CRC 
T-lymphocytes above a threshold level are implicated in tumour regression processes. In 
accordance with our data a study from Salama group demonstrated that FOXP3
+
 cells 
randomly measured in stage II and III CRC tissue were a better positive prognostic marker 
than CD8
+
 and CD45RO
+
 cells 
95
. The prognostic advantage of FOXP3
+ 
cells was shown by 
authors to be significant restricting the analysis to stage II CRCs. Our data expand such 
observation by demonstrating that FOXP3
+
 cells are associated with no antitumour activity in 
stage III CRC. The idea that a marker of T-reg cells might be associated in immuno 
elimination processes is counterintuitive and contrasts with data obtained from other cancers, 
including melanoma
146
 and breast
147
, ovarian
148
, hepatocellular
149,150
 and pancreatic
151
 
cancers. This observation highlight the importance of tumour and tissue type specificity in 
performing mechanistic studies exploring the role of FOXP3 in T-cells antitumour activities. 
The antigen specificity of tumour-infiltrating TRegs (FOXP3
+
) cells has not been established 
in humans and FOXP3 transcription factor might also be expressed by activated effector T 
cells 
61
. On the other hand, it’s conceivable to speculate that increasing levels of FOXP3+ cells 
at the tumour site may reflect a decrease of the chronic inflammatory 
response/circuits/microenvironment at the tumour site, which is thought to facilitate tumour 
progression, while being irrelevant to the acute process that promotes tumour destruction. 
These last hypotheses are corroborated by the evidence that in our study FOXP3
+
 Tils are not 
correlating with CD3
+
 Tils in the overall population of CRC suggesting different pathways of 
recruitment for those immune cells. It is important to underline that the recruitment of CD3
+ 
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and FOXP3
+
TILs in our study seems to be positively and inversely correlated with MSI, 
respectively. However, this result is in contrast with data from Nosho, wherein FOXP3
+
TILs 
densities were significantly higher in patients with MSI cancer than in MSS and from  
Salama, wherein FOXP3
+
 cells densities were not significantly associated with MS-Status 
91, 
95
. Such discrepancies might be explained by differences in measurement standards among 
studies. The study from Nosho analyzed the distribution of FOXP3
+
 TILs densities only in the 
tumour epithelial area while in the study from Salama was performed a random analysis, since 
authors didn’t record whether the tumour tissue location measurement was performed at the 
invading margin or the centre of the tumour 
91,95
. Accordingly, this result suggest that 
FOXP3
+
TILs recruitment in tumour with different MS-Status as genetic background might 
vary whether the analysis is performed at the tumour invasive front or tumour epithelial areas. 
On the other hand it is interesting to mention that by comparing this study with others, CD3
+
 
TILs densities are increased in MSI patients regardless of the fact that measurement was 
performed at the tumour invasive front or at the tumour centre in epithelial areas. The 
harmonization of measurement methodologies in immune infiltrate across studies is a relevant 
issue. Protocol variability of immunohistochemistry in conjunction with inconsistent tissue 
region selection criteria, combined with differences in qualitative and semi-quantitative 
criteria to measure immune infiltration, all contribute to the variability of the results obtained 
among studies and raise the concern that standardization of protocols may be required. It is 
therefore essential to pursue assay uniformity by collaboration among different groups to 
reduce these limitations in order to be able to compare results in the future, and for the 
development of more effective prognostic and predictive markers to improve clinical 
decision-making and understand behaviour of inflammation in the tumour in different settings 
and cancers. 
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